UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

FORM 10-Q

(Mark One)

[X]

QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For Quarterly Period EndedSeptember 30, 20172022

or

[  ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Forthe Transition period fromto ______________to ______________

Commission File Number:000-50099

Commission File Number: IMAGING3, INC.000-50099

GRAPEFRUIT USA, INC.

(Exact name of registrant as specified in its charter)

CALIFORNIAdelaware95-4451059
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)(I.R.S. Employer
Identification No.)

3022 North Hollywood Way, Burbank, California 9150510866 Wilshire Blvd. Ste 225, Los Angeles, CA 90024

(Address of principal executive offices) (Zip Code)

(818) 260-0930310-575-1175

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbol(s)Name of exchange on which registered
Common Stock, $0.0001 par valueGPFTOTCQB

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.0001 par value

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes[X]YesNo [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes[X]YesNo [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One).

Large accelerated filer[  ]Accelerated filer[  ]
Non-accelerated filer[  ]Smaller reporting company[X]
(Donot check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [  ]No[X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

As of November 13, 2017,18, 2022, the number of shares outstanding of the registrant’s class of common stock was 310,082,295.717,402,185.

 

 

 

TABLE OF CONTENTS

Page
PART I.FINANCIAL INFORMATION
Item 1.Condensed Financial Statements (Unaudited)34
Condensed Consolidated Balance Sheets at September 30, 201730,2022 (Unaudited) and December 31, 20162021 (Audited)34
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 20172022 and 20162021 (Unaudited)45
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 20172022 and 20162021 (Unaudited)56
Condensed Consolidated Statement of Stockholders’ Deficit for the Nine Months Ended September 30, 2022 and 2021 (Unaudited)7
Notes to Condensed Consolidated Financial Statements (Unaudited)68
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations1624
Item 3.Quantitative and Qualitative Disclosures About Market Risk1928
Item 4.Controls and Procedures1928
PART II.OTHER INFORMATION
Item 1.Legal Proceedings29
Item 1A.Risk Factors2029
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds2029
Item 3.Defaults Upon Senior Securities2029
Item 4.Mine Safety Disclosures2029
Item 5.Other Information2029
Item 6.Exhibits2029
SIGNATURES2130

2

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements in this Quarterly Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as “believe,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan” and “would.” For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, plans and objectives of management and markets for our common stock are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.

Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout our most recent Annual Report on Form 10-K and any updates described in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K as may be amended, supplemented or superseded from time to time by other reports we file with the U.S. Securities and Exchange Commission (the “SEC”). You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed as exhibits to the reports we file with the SEC, completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this Quarterly Report on Form 10-Q is accurate as of the date hereof. Because the risk factors in our SEC reports could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all the information presented in this Quarterly Report on Form 10-Q, and particularly our forward-looking statements, by these cautionary statements.

3

PART I. FINANCIAL INFORMATION

Item1. CondensedItem 1. Financial Statements (Unaudited)

IMAGING3,GRAPEFRUIT USA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

AT SEPTEMBER 30, 2017 AND DECEMBER 31, 2016

  September 30, 2022
(Unaudited)
  December 31, 2021
(Audited)
 
ASSETS        
         
CURRENT ASSETS:        
Cash $23,583  $9,095 
Accounts receivable  22,977   278,422 
Inventory  337,504   389,282 
Licensee agreement  17,600   37,400 
Prepaid investor relation expense  239,189   - 
Other  3,643   - 
Total current assets  644,496   714,199 
NON-CURRENT ASSETS:        
Property, plant and equipment, net  1,710,639   1,769,627 
Operating right of use - assets  102,475   74,886 
Intangible asset  250,000   250,000 
Other  7,460   7,459 
TOTAL ASSETS $2,715,070  $2,816,171 
         
LIABILITIES AND STOCKHOLDERS’ DEFICIT        
         
CURRENT LIABILITIES        
Notes payable $313,157  $262,839 
Accrued loan interest – nonrelated parties  1,042,864   1,014,653 
Accrued loan interest – related parties  112,029   29,959 
Related party payable  1,465,197   702,581 
Legal settlements - current portion  523,009   541,697 
Subscription payable  319,022   251,727 
Derivative liability  122,965   127,392 
Capital lease - current portion  13,348   31,166 
Operating right of use - liability - current portion  83,313   65,486 
Convertible notes (net of discount of $115,607 and $325,089, respectively)  2,754,690   3,640,959 
Accounts payable and accrued expenses  1,163,727   1,035,114 
Total current liabilities  7,913,321   7,703,573 
         
Capital lease  -   7,669 
Operating right of use - liability  19,162   11,097 
Long-term notes payable, net  911,322   908,617 
Total long-term liabilities  930,484   927,383 
         
TOTAL LIABILITIES  8,843,805   8,630,956 
         
STOCKHOLDERS’ DEFICIT        
Common stock ($0.0001 par value, 1,000,000,000 shares authorized; 606,791,549 and 557,162,744 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively)  60,679   55,716 
Preferred stock ($0.0001 par value, 1,000,000 shares authorized; no shares issued and outstanding as of September 30, 2022 and December 31, 2021)  -   - 
Additional paid in capital  13,251,587   10,962,797 
Accumulated deficit  (19,433,867)  (16,826,164)
Total stockholders’ deficit  (6,121,601)  (5,807,651)
Noncontrolling interest  (7,134)  (7,134)
Total deficit  (6,128,735)  (5,814,785)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $2,715,070  $2,816,171 

  September 30, 2017  December 31, 2016 
  (Unaudited)    
ASSETS        
         
CURRENT ASSETS:        
Cash and cash equivalents $26,079  $22,638 
         
Total current assets  26,079   22,638 
         
PROPERTY AND EQUIPMENT, net  -   - 
Total assets $26,079  $22,638 
         
LIABILITIES AND STOCKHOLDERS’ DEFICIT        
         
CURRENT LIABILITIES        
         
Accounts payable and accrued expenses $802,364  $1,825,080 
Convertible notes payable, net of discount of $220,748 and $115,822 respectively  1,278,232   771,028 
Derivative liability  110,506   5,532,898 
Deferred revenue  27,205   41,829 
Total current liabilities $2,218,307  $8,170,835 
LONG TERM LIABILITIES        
Administrative claims payable $1,026,809  $- 
         
TOTAL LIABILITIES $3,245,116  $8,170,835 
COMMITMENTS AND CONTINGENCIES, note 9  -   - 
         
STOCKHOLDERS’ DEFICIT        
Common stock and additional paid-in capital authorized 1,000,000,000 shares, no par value and 309,313,065 and 243,844,093 issued and outstanding as of September 30, 2017 and December 31, 2016 respectively.  9,417,055   7,829,273 
Accumulated deficit  (12,636,092)  (15,977,470)
Total stockholders’ deficit  (3,219,037)  (8,148,197)
Total liabilities and stockholders’ deficit $26,079  $22,638 

The accompanying notes formare an integral part of these unaudited condensed consolidated financial statements

IMAGING3,

4

GRAPEFRUIT USA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)(Unaudited)

  Three months
ended
September 30,
2017
  Three months
ended
September 30,
2016
  Nine months
ended
September 30,
2017
  Nine months
ended
September 30,
2016
 
             
Net revenues $4,946  $23,195  $14,624  $40,393 
                 
Cost of goods sold  221   1,905   14,263   10,247 
Gross profit  4,725   21,290   361   30,146 
                 
Operating expenses:                
General and administrative expenses  652,178   417,845   1,507,048   2,051,898 
Total operating expenses  652,178   417,845   1,507,048   2,051,898 
                 
Loss from operations  (647,453)  (396,555)  (1,506,687)  (2,021,752)
                 
Other income (expense):                
Interest expense  (120,691)  (764,619)  (542,047)  (2,723,355)
Change in value of derivative instruments  72,277   138,407   1,714,502   (1,626,839)
Gain on extinguishment of debt  -   -   3,668,776   - 
Other income  28,233   48,667   7,633   256,135 
Total other income (expense)  (20,181)  (577,545)  4,848,864   (4,094,059)
                 
Income (loss) before income taxes  (667,634)  (974,100)  3,342,177   (6,115,811)
                 
Provision for income taxes  -   -   800   800 
                 
Net income (loss) $(667,634) $(974,100) $3,341,377  $(6,116,611)
                 
Net income (loss) per share - Basic $(0.00) $(0.01) $0.01  $(0.03)
Net income (loss) per share - Diluted $(0.00) $(0.01) $0.01  $(0.03)
Weighted average common stock outstanding - Basic  289,109,736   194,813,806   265,366,406   205,139,866 
Weighted average common stock outstanding - Diluted  289,109,736   194,813,806   286,364,229   205,139,866 
  Three months ended  Three months ended  Nine months ended  Nine months ended 
  September 30, 2022  September 30, 2021  September 30, 2022  September 30, 2021 
Revenue $2,962  $153,476  $32,673  $586,780 
Cost of goods sold  62,758   346,073   297,069   926,671 
Gross loss  (59,796)  (192,597)  (264,396)  (339,891)
Operating expenses:                
Sales  1,172   3,800   6,744   5,760 
General and administrative  341,662   411,319   1,303,607   1,341,977 
Total operating expenses  342,834   415,119   1,310,351   1,347,737 
                 
Loss from operations  (402,630)  (607,716)  (1,574,747)  (1,687,628)
Other income (expense):                
Interest expense  (369,763)  (388,273)  (1,143,443)  (1,258,650)
Change in value of derivative instruments  14,187   13,877   138,081   91,210 
Gain (loss) on extinguishment of debt  -   -   (27,593)  (398,373)
Loss on extinguishment of debt - related parties  -   -   -   (491,998)
Total other expense  (355,576)  (374,396)  (1,032,955)  (2,057,811)
                 
Loss before income taxes  (758,207)  (982,112)  (2,607,703)  (3,745,439)
                 
Tax provision  -   -   -   - 
                 

Net loss

  (758,207)  (982,112)  (2,607,703)  (3,745,439)
                 
Loss attributable to noncontrolling interest      

(270

)      

(270

)
                 
Net loss attributable to Grapefruit USA, Inc. $

(758,207

) $

(981,842

) $

(2,607,703

) $

(3,745,169

)
                 
Net loss per share – Basic and diluted $(0.00) $(0.00) $(0.00) $(0.01)
Weighted average common stock outstanding - Basic and diluted  573,580,207   550,277,467   589,362,360   515,339,023 

The accompanying notes formare an integral part of these unaudited condensed consolidated financial statements

IMAGING3,

5

GRAPEFRUIT USA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED

SEPTEMBER 30, 2017 AND 2016(Unaudited)

  Nine months
ended
  Nine months
ended
 
  September 30, 2022  September 30, 2021 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss $(2,607,703) $(3,745,169)
Adjustments to reconcile net loss to net cash used for operating activities:        
Net loss attributable to non-controlling interest  -   (270)
Depreciation and amortization expense  58,988   69,598 
Amortization of debt discount  313,731   692,129 
Change in value of derivative  (138,081)  (91,210)
Loss on extinguishment of debt - related parties  -   491,998 
Loss on extinguishment of debt  -   398,373 
Stock-based compensation for services  301,996   265,024 
Interest expense  1,143,443   - 
Stock option expense  27,006   65,754 
Loss on bad debts  250,054   - 
Loss on legal settlement  36,462   - 
Loss on inventory valuation  68,941   - 
Changes in operation assets and liabilities:        
Accounts Receivables  5,390   (261,452)
Inventory  (17,163)  91,434 
Prepaid expense and current assets  16,157   (6,875)
Right-of-use assets  (27,588)  68,844 
Hemp investment  -   85,000 
Derivatives  133,654   - 
Accounts payable  128,613   70,785 
Accrued executive compensation  450,000   - 
Accrued expenses and other current liabilities  -   487,792 
Accrued loan interest expense  (487,344)  388,940 
Right-of-use liability  25,892   (69,276)
Net cash (used for)/provided by used for operating activities  (317,552)  (998,581)
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Net cash received from acquisition  -   69 
Purchase of land and equipment  -   (62,319)
Net cash used for investing activities  -   (62,250)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Principal repayment of capital lease liability  (25,487)  (49,062)
Repayment of legal liability  (8,112)  (16,393)
Proceeds from convertible notes (net of discount $97,703)  6,547   450,000 
Proceeds from loans, net  56,000   - 
Repayment of loan principal  (9,524)  (4,772)
Proceeds from related party notes  320,751   93,080 
Repayment of related party note principal  (8,135)  - 
Contributions from non-controlling interest  -   400 
Proceeds from exercise of warrants  -   250,000 
Proceeds from sale of common stock  -   75,000 
Net cash proceeds from financing activities  332,040   798,253 
         
NET INCREASE (DECREASE) IN CASH  14,488   (262,578)
         
CASH, BEGINNING BALANCE  9,095   299,895 
         
CASH, ENDING BALANCE $23,583  $37,317 
         
SUPLEMENTAL DISCLOSURE ON CASH FINANCING ACTIVITY        
Cash paid for interest expense  80,551   87,883 
SUPLEMENTAL DISCLOSURE ON NON-CASH FINANCING ACTIVITY        
Shares issued for legal settlement  47,039   1,090,462 
Shares issued for conversion of notes payable  1,745,818   996,620 
Shares issued for debt settlement with related parties  -   699,236 
Shares issued for compensation  139,614   - 
Shares issued for acquisition  -   250,000 

(UNAUDITED)

  Nine months ended  Nine months ended 
  September 30, 2017  September 30, 2016 
       
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net income (loss) $3,341,377  $(6,116,611)
Adjustments to reconcile net income (loss) to net cash used for operating activities:        
Non Cash Interest  427,097   2,675,797 
Stock based compensation  -   139,535 
(Gain) loss on extinguishment of debt  (3,668,776)  - 
Change in value of derivatives  (1,714,502)  1,626,839 
Shares issued for services  648,300   1,612,500 
Warrants issued for service  194,956   - 
(Increase) / decrease in current assets:        
Accounts receivable  -   51,505 
Increase / (decrease) in current liabilities:        
Accounts payable and accrued expenses  207,578   (345,869)
Deferred revenue  (14,624)  (38,393)
Net cash used for operating activities  (578,594)  (394,697)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from issuance of notes payable  575,035   295,000 
Proceeds from sale of stock, net of offering costs  7,000   159,900 
Net cash provided from financing activities  582,035   454,900 
         
NET INCREASE IN CASH & CASH EQUIVALENTS  3,441   60,203 
         
CASH & CASH EQUIVALENTS, BEGINNING BALANCE  22,638   9,508 
CASH & CASH EQUIVALENTS, ENDING BALANCE $26,079  $69,711 
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITY        
Notes and accrued interest converted to common stock $196,797  $- 
Promissory notes issued for no cash consideration $151,222  $- 
Compensation paid through exercise of options $200,000  $- 

The accompanying notes formare an integral part of these unaudited condensed consolidated financial statements

IMAGING3, INC.

Notes to Condensed Financial Statements

(Unaudited)

6

 

1.

GRAPEFRUIT USA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

(Unaudited)

  Shares  Amount  Capital  Deficit  Deficit  Interest  Deficit 
  Deficit Attributable to Grapefruit USA, Inc.             
  Common Stock  Additional     Total  Non-    
  Number of     Paid in  Accumulated  Stockholders’  controlling  Total 
  Shares  Amount  Capital  Deficit  Deficit  Interest  Deficit 
                      
Balance as of December 31, 2020  505,700,437  $50,570  $6,591,177  $(11,321,494) $(4,679,747) $-  $(4,679,747)
                             
Shares issued for services  7,449,937   745   302,799   -   303,544   -   303,544 
                             
Shares issued for settlement  8,404,186   840   1,089,620   -   1,090,460   -   1,090,460 
                             
Shares issued upon warrant exercise  2,000,000   200   249,800   -   250,000   -   250,000 
                             
Shares issued for note conversion  13,352,264   1,335   995,285   -   996,620   -   996,620 
                             
Shares issued for related party  11,710,465   1,171   1,190,063   -   1,191,234   -   1,191,234 
                             
Stock options granted pursuant to board of director agreement  -   -   65,754   -   65,754   -   65,754 
                             
Shares issued for purchase of stock  1,000,000   100   74,900   -   75,000   -   75,000 
                             
Shares issued for acquisition  4,545,455   455   249,545   -   250,000   -   250,000 
                             
Equity investment  -   -   (7,736)  -   (7,736)  (7,033)  (14,769)
                             
Net loss  -   -   -   (3,745,169)  (3,745,169)  (270)  (3,745,439)
                             
Balance as of September 30, 2021  554,162,744  $55,416  $10,801,207  $(15,066,663) $(4,210,040) $(7,303) $(4,217,343)
                             
Balance as of December 31, 2021  557,162,744  $55,716  $10,962,797  $(16,826,164) $(5,807,651) $(7,134) $(5,814,785)
                             
Shares issued for services  24,025,354   2,403   471,487   -   473,890   -   473,890 
                             
Shares issued for settlement  2,325,878   233   46,806   -   47,039   -   47,039 
                             
Shares issued for note conversion  23,277,573   2,327   1,743,491   -   1,745,818   -   1,745,818 
                             
Stock options granted pursuant to board of director agreement      -   27,006   -   27,006   -   27,006 
                             
Net loss  -   -   -   (2,607,703)  (2,607,703)  -   (2,607,703)
                             
Balance as of September 30, 2022  606,791,549  $60,679  $13,251,587  $(19,433,867) $(6,121,601) $(7,134) $(6,128,735)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

7

GRAPEFRUIT USA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2022

NOTE 1 – ORGANIZATION AND DESCRIPTIONNATURE OF BUSINESSOPERATIONS

Imaging3,Overview

Grapefruit Boulevard Investments, Inc. (the “Company”(“we”, “our”, “us”, “we”“Grapefruit”, “Imaging3”“GBI”, or “the Company”) iswas formed as a California corporation incorporated on October 29, 1993 as Imaging Services, Inc. The Company filed a certificate of amendment of articles of incorporation to change its name toAugust 28, 2017 and began operation in September 2017. On July 10, 2019, Grapefruit acquired Imaging3, Inc. on August 20, 2002.(“IGNG”) in a reverse acquisition (the “Acquisition”). Under the terms of a Share Exchange Agreement by and among IGNG, Grapefruit and Grapefruit’s shareholders, IGNG issued to Grapefruit’s existing shareholders approximately 81% of the post-Acquisition IGNG common shares and the IGNG shareholders retained 19% of the post-Acquisition IGNG common shares. As a result, our financial statements are prepared using the acquisition method of accounting with Grapefruit as the accounting acquirer and IGNG treated as the legal acquirer and accounting acquiree. On December 16, 2019, Grapefruit filed the necessary paperwork with the Financial Industry Regulatory Authority (“FINRA”) and OTC Markets to effect the Company Name and Ticker symbol changes from “IGNG” to “GPFT” formally changing our corporate name from Imgaing3, Inc. to Grapefruit USA, Inc., a Delaware corporation whose stock is trading under the Ticker Symbol “GPFT”.

The Company’s primary business is refurbishmentannual distribution licensure renews again on June 13, 2023. Our annual manufacturing license was renewed by the California Department of Health. Grapefruit has not yet applied for a license to cultivate cannabis flowers and salewill not until construction of medical equipment, partsour cultivation facility has been substantially completed. We own two acres of fully entitled cannabis real property located in the Coachillin’ Industrial Cultivation and servicesAncillary Canna-Business Park where we intend to hospitals, surgery centers, research labs, physician officesbuild a 30,000 square foot fully licensed cannabis facility as more fully described below. The location within Coachillin’ allows the Company to apply for and veterinarians. Equipment sales include new c-arms, c-arms tables, remanufactured c-arms, used c-armhold every cannabis license available under the California Cannabis laws.

The “Mothership” Cultivation & Lab Facility

In July 2021, Grapefruit obtained a development permit to build a 30,000 square foot “Mothership” facility intended to house a state-of-the-art indoor grow as well as a separately licensed distribution hub and surgical tables. Part sales comprise new or renewed replacement partslaboratory that will produce the patented Hourglass line of topical creams as well as high quality extracts from trim generated by processing the indoor cannabis flowers. We intend to obtain CGMP certification for c-arms.

The Company has developed a proprietary medical technology designed to produce 3D medical diagnostic images in real time. We believe Imaging3 technology has the potential to contributelab pursuant to the improvement of healthcare. Our technology is designed to cause 3D images to be instantly constructed using high-resolution fluoroscopy. These images can be used as real time references for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or inGood Manufacturing Practice regulations enforced by the human body. This technology is still in development and the Company intends to seek approval from the Food andFederal Drug Administration (“FDA”). We expect that our facility will meet proper design, monitoring, and manufacturing control processes to assure the strength, quality, and purity of all Hourglass products we manufacture. We anticipate the FDA to mandate all cannabis facilities to be CGMP certified (Current Good Manufacturing Practice regulations enforced by the FDA) to continue in operation if cannabis becomes legalized by the federal government.

Summit Boys

In August 2021, the Company purchased control of Summit Boys, Inc., a cannabis extraction brand with product lines in retail stores throughout the State of California. The Company is continuing the Summit Boys’ business without interruption and is currently selling its branded products in California through Grapefruit.

Summit Boys’ premium extracts include sugar, crumble, badder, live resin, diamonds, budder, sauce, caviar and other extracted cannabis products, which are currently placed in licensed dispensaries throughout California and are protected by United States of America Trademark Reg. No. 6406802, July 6, 2021.

Grapefruit’s Business Development

In December 2020, we shifted our corporate focus from distribution operations to further development of our patented Hourglass™ Time Release THC+CBD-Infused Topical Cream. Hourglass is the first and only patented Full Spectrum THC+ Cannabinoid Topical delivery Cream that provides its users with a full body, synergistic entourage effect that was previously only available by smoking, vaping or eating cannabis products such as cannabis flowers and gummies. Our Topical Cream is scientifically designed to deliver the full effects of THC combined with a broad range of cannabinoids for a user’s overall health, wellness, and well-being. Hourglass products are laboratory tested. Test results published on every package via a designated QR Code. There is no other topical cream product on the market with our patented technology that provides users with the holistic benefits of the entourage effect of THC+CBD, CBN, CBG, Delta8, THCV and CBE. Hourglass™ is currently available in licensed retail and mobile cannabis dispensaries in Central California and Los Angeles County, California, USA. Hourglass™ is not intended for use to cure, mitigate, treat, or prevent disease and we are not making any such claims.

In July 2021, we decided to bring our patented Hourglass™ Time Release THC+CBD-Infused Topical Cream to the federally legalized Canadian cannabis marketplace. In January 2022, the company’s licensed Canadian distribution partner Medz Cannabis filed a Notice of New Cannabis Product (“NNCP”) with Health Canada on Grapefruit’s behalf for its Hourglass THC+CBD Topical cream. Health Canada is the Canadian federal government department that is responsible for national health policy. It approves and oversees the production of all cannabis products and is the licensing authority for all companies involved in the cannabis industry. Health Canada requires that all cannabis products meet federal regulatory requirements before they can be sold in Canada. Under Canada’s Federal Cannabis Regulatory scheme, Health Canada must be notified of a company’s intent to sell a cannabis product that has not previously been sold in the country.

8

On March 21, 2022, Health Canada approved the Company’s NNCP application authorizing Grapefruit to sell its patented Hourglass™ Time Release THC+CBD-Infused Topical Cream to licensed retail outlets throughout Canada under NNCP ID No. NP-V2EHUWO907.

In March 2022, we expanded our distribution efforts to include retail and wholesale sales of our Summit Boys branded products in California.

In September 2022, the Company entered into an exclusive licensing agreement with WWE Hall of Fame wrestler and cannabis pioneer Rob Van Dam to bring his branded cannabis products to the California retail marketplace. Rob Van Dam (“RVD”) is an American professional wrestler and actor best known for his tenures in Extreme Championship Wrestling (ECW), World Wrestling Entertainment (WWE) and Total Nonstop Action Wrestling (TNA)/Impact Wrestling. Van Dam is one of only two wrestlers in history to have held the WWE, ECW and TNA world championships. He was voted “Most Popular Wrestler” by readers of Pro Wrestling Illustrated magazine in 2001 and again in 2002. WWE named him the greatest star in ECW history in 2014.

Grapefruit holds its State of California annual licensing from the Bureau of Cannabis Control and the California Department of Public Health. The Company has a permanent annually renewable license as opposed to a provisional or temporary one. The Company is one of the earliest registered distribution companies in the State of California to have an annually renewable license as opposed to the provisional licenses previously granted.

Grapefruit operates within the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park (the “Park”), located in Desert Hot Springs, California, 14 miles north of downtown Palm Springs. The Park is the first and largest cooperative canna-business compound of its kind. It is unique in that the landowners each own a proportionate interest in a collaborative owner’s association, which allows them to share much of the park overhead such as clean cultivation water, park security and access to agricultural power rates.

Distribution

In early 2021, the Company temporarily suspended its ‘bulk’ purchase and distribution of wholesale cannabis flower due to negative market forces in the wholesale cannabis market beyond the control of the Company. The Company can and will resume wholesale ‘bulk’ cannabis sales and distribution operations when market forces indicate such resumption is appropriate. Nonetheless, the Company continues to distribute ‘bulk’ concentrates to support our Summit Boys brand in California. In March 2022, we expanded our distribution efforts to include retail and wholesale sales of our Summit Boys branded products in California.

Manufacturing

The Company owns a fully licensed ethanol extraction facility in the City of Desert Hot Springs, CA. The Company owns and operates a Type 6 Ethanol Extraction Plant which removes the essential cannabis compounds, such as THC Distillate, that we, and others use, to produce cannabis products.

Grapefruit manufactures its patented Hourglass™ Time Release THC+CBD-Infused Topical Cream at its Coachillin’ facility which allows us to maintain strict quality control standards. In addition, Grapefruit’s extraction lab produces high quality distillate or “Honey Oil” from cannabis trim sourced by Grapefruit. THC Honey Oil is a fundamental cannabis commodity which serves as the active ingredient in products from infused edibles to tinctures/creams. Grapefruit chose to set up its extraction laboratory in the City of Desert Hot Springs because, among other factors, the city does not tax the manufacture of oil by Grapefruit at its Desert Hot Springs extraction facility, thereby providing Grapefruit with an additional competitive advantage.

Binding Letter of Intent to Acquire Diagnostic Lab Corporation

On March 22, 2022, the Company entered into a Memorandum of Understanding with Diagnostic Lab Corporation, Inc., a Delaware corporation (“DLC”). On June 30, 2022, the Company entered into a Binding Letter of Intent (“LOI”) with DLC. Pursuant to the LOI, the Company will acquire the assets of DLC, its IP and all of its affiliated entities for a combination of cash and a to-be-determined number of the Company’s $0.0001 par value common stock. The Company and DLC will jointly recapitalize the Company by raising $12.5 million (inclusive of a currently committed $5.5 million debt facility) which will enable the Company to construct its Good Manufacturing Practices (“cGMP”) certified Desert Hot Springs, CA, Coachillin Park. The “Mothership” facility which will house a state-of-the-art indoor cultivation, manufacturing laboratory and distribution facility. In addition, the recapitalization will fund the Company’s Hourglass 510K Project, the Medical Study of the effects of Hourglass powered products on osteoarthritis sufferers and afford sufficient working capital and interest payment reserves to allow usthe post-transaction Company to offer our product to healthcare providers.reach positive cash flow. As of September 30, 2022, the Company is in the process of finalizing its due diligence on DLC and is in the final stages of negotiating the terms of its anticipated financing and structuring of the transaction documents.

9

 

2.

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis

The condensed consolidated interim financial statements of Presentation

On September 13, 2012 (the “Petition Date”), the Company filed a voluntary petitionGrapefruit USA, Inc. are unaudited. They have been prepared in accordance with the federal bankruptcy courtGenerally Accepted Accounting Principles in Los Angeles, California, to enter bankruptcy under Chapter 11 of the United States Bankruptcy Code. On or about July 15, 2013, our Plan of Reorganization was approved by the United States Bankruptcy Court. On July 30, 2013, we emerged from bankruptcy and continued operations under the terms and conditions of our Bankruptcy Reorganization Plan as it applies to post bankruptcy operations. For accounting purposes, management deemed the effective date of the Chapter 11 Plan (the “Plan”(“U.S. GAAP”) to be June 30, 2013. The Company’s operations between July 1, 2013 and July 30, 2013 were not significant. The Plan adopted by Imaging3, Inc. is a reorganizing plan. Payments under the Plan were made by utilizing existing cash on hand, borrowings on a secured and unsecured basis, future cash flow, if any, capital raised through the sale of our common stock in private placements, and by conversion of debt to equity.

Upon emergence from bankruptcy, Imaging3 adopted fresh-start accounting which resulted in Imaging3 becoming a new entity for financial reporting purposes. Imaging3 applied fresh start accounting as of July 1, 2013. As a result of the application of fresh start accounting and the effects of the implementation of the plan of reorganization, the financial statements on or after July 1, 2013 are not comparable with the financial statements prior to that date.

The accompanying unaudited interim financial statements havebeenpreparedinaccordanceinformation and with theapplicable rules and regulations of the U.S. Securities and Exchange Commissionforthe presentation of relating to interim financial information, butstatements. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principlesU.S. GAAP for complete financial statements. In the opinion of management, all adjustments consisting(consisting of normal recurring adjustments,accruals) considered necessaryfora fair presentation have been included. ItissuggestedOperating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that thesemay be expected for any other reporting period.

These condensed consolidated interim financial statements should be readinconjunction with the Company’s audited consolidated financial statements and related notes thereto included in the Company’s annual reportits Annual Report on Form 10-K for the fiscal year ended December 31, 2016. The2021.

Basis of ConsolidationSubsidiaries are entities controlled by the Company. Control exists when the Company followseither has a controlling voting interest or is the same accounting policiesinpreparation of interim reports. Results of operationsforthe interim periods are not indicative of annual results.

Going Concern

The Company’s financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has historically incurred net losses. The continuing losses have adversely affected the liquidity of the Company.

In view of the matters described in the preceding paragraph, recoverabilityprimary beneficiary of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and to succeed in its future operations.variable interest entity. The financial statements do not include any adjustments relating toof subsidiaries are included in the recoverability and classification of recorded asset amounts or amounts and classification of liabilitiesconsolidated financial statements from the date that might be necessary as a result ofcontrol commences until the Company’s going concern uncertainty. Management believes there is substantial doubt about the Company’s ability to continue as a going concern.date that control ceases. All significant intercompany transactions are eliminated.

 

Management’s plan regarding this matter is to, amongst other things, seek additional debt or equity financing, increaseIn August 2021, the Company entered into a Stock Purchase Agreement acquiring the majority ownership and control of Summit Boys, Inc., a very well-known and established cannabis extraction brand with product lines in retail stores throughout the State of California. The Company plans on continuing the business without interruption and plans on licensing the Summit Boys brand in the State of Oklahoma under that State’s newly enacted legalized statutory scheme for cannabis products. This non-significant and non-operating subsidiary has been consolidated with Grapefruit’s financial statements. As consideration, the Company issued 4,545,455 shares of common stock for 51% ownership if Summit Boys, Inc. There was no activity for the nine months ended September 30, 2022.

SegmentsWe have two reporting segments: Retail and Wholesale. For the three months ended September 30, 2022, we generated 70.5% of our total revenues from our retail segment and 29.5% of our total revenues from our wholesale segment. For the three months ended September 30, 2021, we generated 2.4% of our total revenues from our retail segment and 97.6% of our total revenues from our wholesale segment. For the nine months ended September 30, 2022, we generated 78.5% of our total revenues from our retail segment and 21.5% of our total revenues from our wholesale segment. For the nine months ended September 30, 2021, we generated 1.3% of our total revenues from our retail segment and 98.7% of our total revenues from our wholesale segment.

Our retail operations generate revenue primarily through the sale of our Summit Boys branded product, THC “Honey Oil” tinctures, and CBD-Infused Hourglass™ Topical Cream products through our online and third-party sales volume, and continue seeking approvalchannels. Our wholesale revenues are generated from the FDA to bringtomarket our smart scan technology imaging platform. We cannot assure you that funds from these sources will be available when needed or, if available, will be on terms favorabletous ortoour stockholders.Ifwe raise additional funds or settle liabilities by issuing equity securities, the percentage ownershipsales of our stockholders will be reduced, stockholders may experience additional dilution or such equity securities may provide for rights, preferences or privileges senior to those of the holders ofTHC-Infused Hourglass™ Topical Cream, RSO syringes, vape cartridges, and flower products through our common stock. Our ability to executepre-existing and newly acquired customers.

Financial information about our business plansegments and continue as a going concern may be adversely affectedifweare unablegeographical areas is provided in Note 14, Segment Information, to raise additional capital or operate profitably.our consolidated financial statements in Part I, Item 1, “Notes to Condensed Consolidated Financial Statements (Unaudited),” in this Quarterly Report on Form 10-Q.

The Company anticipates that further equity/debt financings will be necessary to continue to fund operations in the future and there is no guarantee that such financings will be available or, if available, on acceptable terms.

A summaryUse of the Company’s significant accounting policies consistently applied in theEstimates – The preparation of the accompanying financial statements follows:

Use of Estimates

In preparingour financial statements in conformity with accounting principles generally acceptedinthe United States of America, management is requiredU.S. GAAP requires us tomake estimates, assumptions and assumptionsjudgments that affect the reported amounts of assetsandliabilities and the disclosure of contingent assetsandliabilities atas of the date of theour financial statements and the reported amounts of revenues and expenses during the reporting period.Actualperiods presented.

10

We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from those estimates.these estimates, making it possible that a change in these estimates could occur in the near term. The company’s most significant estimates related to useful life for depreciation, the value of long-lived assets and related impairment, and provision for income taxes of property and equipment.

CashInventory– Inventory is valued at the lower of cost and Cash Equivalents

The Company considers all liquid investments with a maturitynet realizable value, determined using weighted average cost. All direct and indirect costs related to inventory are capitalized as they are incurred, and they are subsequently recorded in cost of three months or less fromgoods sold on the date of purchase that are readily convertible into cash to be cash equivalents. The Company maintains its cash in bank deposit accounts that may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company had no cash equivalents at September 30, 2017.

Revenue Recognition

Revenueisrecognized upon shipment, provided that evidence of an arrangement exists, title and riskstatements of loss have passedtoand comprehensive loss at the customer, fees are fixed or determinabletime inventory is sold. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and collectiontransportation. At the end of the related receivable is reasonably assured. Revenueisrecorded net of estimated product returns, which isbasedupon the Company’s return policy, sales agreements, management estimates of potential future product returns relatedtocurrent period revenue, current economic trends, changesincustomer composition and historical experience. The Company accrues for warranty costs, sales returns, and other allowances based onitsexperience. Generally, the Company extends credit to its customers and does not require collateral.TheCompany performs ongoing credit evaluations of its customersandhistoric credit losses have been within management’s expectations and has a revenue receivables policy for serviceandwarranty contracts. Equipment sales usually have a one-year warranty of parts and service. After a one-yeareach reporting period, the Company contactsperforms an assessment of inventory and records write-downs for excess and obsolete inventories based on the buyerCompany’s estimated forecast of product demand, production requirements, market conditions, regulatory environment, and spoilage. Actual inventory losses may differ from management’s estimates and such differences could be material toinitiate the saleCompany’s statements of financial position, statements of loss and comprehensive loss and statements of cash flows. When inspecting inventory this quarter, we found some inventory was damaged, which necessitated a new warranty contractforone year. Warranty revenues are deferred and recognized on a straight line basis over the term$68,941 reduction in inventory. Most of the contract or as services are performed.product was salvageable and will be ready for resale in November 2022.

Deferred Revenue

Deferred revenue consists substantially of amounts received from customers in advance of the Company’s performance service period. Deferred revenue is recognized as revenue on a systematic basis that is proportionate to the period that the underlying services are rendered, which in certain arrangements is straight-line over the remaining contractual term or estimated customer life of an agreement.

Accounts Receivable

The Company’s customer base is geographically dispersed. The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivableProperty, Plant and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. Reserves are recorded primarily on a specific identification basis.

Property & Equipment,

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to expenses as incurred and additions, renewals and betterments are capitalized. When net– Our property and equipment are retired or otherwise disposedrecorded at cost. Assets held under capital leases are capitalized at the commencement of the relatedlease at the lower of the present value of minimum lease payments at the inception of the lease or fair value. Maintenance and repairs are expensed as incurred. Depreciation is computed using the straight-line method over estimated useful lives of four to seven years, and amortization is computed using the straight-line method over the life of the applicable lease. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from the respectiveour accounts and any resulting gain or loss is reflected in our consolidated statements of operations.

Land Improvements – Our land improvements are recorded at cost provided by our property association and is included in operations. Depreciation ofthe property, plant and equipment is provided usingequipment. These costs will continue to be capitalized until construction has been completed. Land improvements will not be depreciated until the straight-line method for all assets with estimated lives of three to eight years.construction has been completed by the property association.

Impairment of Long-Lived Assets

Long-lived Impairment Assessment – Our long-lived assets are reviewed forsubject to an impairment whenever events or changes in circumstances indicatetest if there is an indicator of impairment. The carrying value and ultimate realization of these assets is dependent upon our estimates of future earnings and benefits that we expect to generate from their use. If our expectations of future results and cash flows are significantly diminished, other long-lived assets may be impaired and the resulting charge to operations may be material. When we determine that the carrying amountvalue of an assetintangibles or other long-lived assets may not be recoverable throughbased upon the estimatedexistence of one or more indicators of impairment, we use the projected undiscounted cash flows expectedflow method or realizable value to resultdetermine whether an impairment exists, and then measure the impairment using discounted cash flows.

Revenue Recognition– The Company derives revenues from the use and eventual dispositionsale of product in accordance to ASC Topic 606. Revenues are recognized when control of the assets. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value.

The Company tests long-lived assets, including property, plant, equipment and intangible assets subject to periodic amortization, for recoverability at least annuallypromised goods or more frequently upon the occurrence of an event or when circumstances indicate that the net carrying amountservices is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. The Company considers historical performance and future estimated results in its evaluation of potential impairment, and then compares the carrying amount of the assettransferred to the future estimated cash flows expected to result fromcustomer in an amount that reflects the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows,consideration the Company measures the amount of impairment by comparing the carrying amount of the assetexpects to its fair value. The estimation of fair valuebe entitled to in exchange for transferring those goods or services.

Revenue is generally measured by discounting expected future cash flows at the rate the Company utilizes to evaluate potential investments. The Company estimates fair valuerecognized based on the information available in making whatever estimates, judgments and projections are considered necessary.following five step model:

-Identification of the contract with a customer
-Identification of the performance obligations in the contract
-Determination of the transaction price
-Allocation of the transaction price to the performance obligations in the contract
-Recognition of revenue when, or as, the Company satisfies a performance obligation

11

 

Performance ObligationsSales of products are recognized when all the following criteria are satisfied: (i) a contract with an end user exists which has commercial substance; (ii) it is probable the Company will collect the amount charged to the end user; and (iii) the Company has completed its performance obligation whereby the end user has obtained control of the product. A contract with commercial substance exists once the Company receives and accepts a purchase order or once it enters into a contract with an end user. If collectability is not probable, the sale is deferred and not recognized until collection is probable or payment is received. Control of products typically transfers when title and risk of ownership of the product has transferred to the customer. For contracts with multiple performance obligations, the Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. The Company uses an observable price to determine the stand-alone selling price for separate performance obligations or a cost-plus margin approach when one is not available. Historically the Company’s contracts have not had multiple performance obligations. The large majority of the Company’s performance obligations are recognized at a point in time related to the sale of products.

Cost of Goods Sold– Our cost of goods sold includes the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labelling of cannabis products; personnel-related costs, fees for third-party services, such as testing and transportation costs related to our distribution services.

Basic and Diluted Net Income Per Share

Basic net income per share is based upon the weighted average number of common shares outstanding. Diluted net income per share is basedonthe assumptionassumes that all dilutive convertible shares and stock options were converted or exercised. Dilutioniscomputed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (oratthetime of issuance,iflater), and asiffunds obtained thereby were usedtopurchase common stock at the average market price during the period. During 2016, potentially dilutive securities were excluded from the computation of weighted average shares outstanding-diluted because their effect was anti-dilutive.

Numerator:   
Net income attributable to common shareholders, for the nine months ended September 30, 2017 $3,341,377 
     
Denominator:    
Weighted-average number of common shares outstanding during the period  265,366,406 
Dilutive effect of stock options, warrants, and convertible promissory notes  20,997,823 
Common stock and common stock equivalents used for diluted earnings per share  286,364,229 

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

  September 30, 2022  December 31, 2021 
Numerator:        
Net loss attributable to common shareholders $(2,607,703)  (5,504,670)
Denominator:        
Weighted-average number of common shares outstanding during the period  589,362,360   515,339,023 
Dilutive effect of stock options, warrants, and convertible promissory notes  -   - 
Common stock and common stock equivalents used for diluted earnings per share $(0.00) $(0.01)

Derivative Financial Instruments

- The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financingtofund its business needs, including convertible notes and warrants and other instruments not indexedtoour stock. The Companyisrequiredtorecord its derivative instruments at their fair value. Changesinthe fair value of derivatives are recognizedinearnings in accordance with ASC 815. The Company’s only asset or liability measuredatfair value on a recurring basisisits derivative liability associated with warrants to purchase common stock and convertible notes.

Fair Value of Financial Instruments

The– We value our financial assets and liabilities using fair value accounting standard createsmeasurements. Fair value is based on the price that would be received to sell an asset or paid to transfer a three-level hierarchy to prioritizeliability in an orderly transaction between market participants at the measurement date. Assets and liabilities measured at fair value are categorized based on whether the inputs usedare observable in the market and the degree that the inputs are observable. The categorization of financial instruments within the valuation techniqueshierarchy is based on the lowest level of input that is significant to derive fair values. The basis forthe fair value measurements for each level within themeasurement. The hierarchy is described below withprioritized into three levels (with Level 3 being the lowest) defined as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.

12

Level 2: Observable inputs other than prices included in Level 1, havingsuch as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated with observable market data.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the highest priorityfair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies, and similar techniques that use significant unobservable inputs.

The carrying amount of our cash and cash equivalents approximates fair value because of the short-term nature of the instruments. The carrying amount of our notes payable at December 31, 2019, approximates their fair values based on comparable borrowing rates available to the company.

There have been no changes in Level 1, Level 2, and Level 3 having the lowest.

Level 1: Observable prices in active markets for identical assets or liabilities.
Level 2: Observable prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in the market.
Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable. These unobservable assumptions reflect estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques include use of option pricing models, discounted cash flow models, and similar techniques.

The Company had the followingcategorizations and no changes in valuation techniques for these assets or liabilities for the nine months ended September 30, 2022 and year ended December 31, 2021.

SUMMARY OF DERIVATIVE LIABILITIES

             
  Level 1  Level 2  Level 3  Total 
Derivative Liabilities September 30, 2022 $-  $-  $122,965  $122,965 
Derivative Liabilities December 31, 2021 $-  $-  $127,392  $127,392 
Derivative Liabilities $-  $-  $127,392  $127,392 
                

Items measured at fair value on a recurringnon-recurring basis

The Company’s prepaids and other current assets, long lived assets, including property and equipment, and goodwill are measured at September 30, 2017.fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

  Level 1  Level 2  Level 3  Total 
Derivative Liabilities $-  $-  $110,506  $110,506 

Income Taxes

The Company accounts for income taxes in accordance with ASC 740-10, “Income Taxes” which requires the recognition of deferred – Income tax assets and liabilities forare recorded using the expected futureasset and liability method. Under the asset and liability method, tax consequences of events that have been included in the financial statements or tax returns.

Under this method, deferred income taxesassets and liabilities are recognized for the tax consequences in future years ofattributable to differences between thefinancial statement carrying amounts of existing assets and liabilities and their respective tax bases of assetsas well as net operating loss andliabilitiesandtheir financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expectedtoaffect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assetstothe amount expectedtobe realized. The provision for income taxes represents the tax payableforthe period and the change during the period in deferredcredit carryovers. Future tax assets and liabilities.

Inventory

Inventory is stated at the lower of cost or net realizable value with cost determinedliabilities are measured using the first-in, first-out method.

Researchenacted tax rates expected to apply when the asset is realized, or the liability settled. The effect on future tax assets and Development

Costs and expenses that can be clearly identified as research and development are charged to expense as incurredliabilities of a change in accordance with FASB ASC 730-10. Includedtax rates is recognized in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, and overhead directly related to the Company’s research and development operations, as well as costs to acquire technology licenses.

Recent Accounting Pronouncements

In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09,Revenue from Contracts with Customers. The standard will eliminate the transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 is effective for annual and interim periods beginning after December 15, 2017. Early adoption is not permitted. The revenue recognition standard is required to be applied retrospectively, including any combination of practical expedients as allowedincome in the standard. We are evaluatingperiod that enactment occurs. To the impact, if any, of the adoption of ASU 2014-09 to our financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In August 2014, the FASB issuedASU2014-15,Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.ASU2014-15 changes to the disclosure of uncertainties about an entity’s abilitytocontinue as a going concern. These changes require an entity’s managementtoevaluate whether there are conditions or events, consideredinthe aggregate,extent that raise substantial doubt about the entity’s abilitytocontinue as a going concern within one year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within one year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be madeinthe financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or eventsinrelation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intendedtoat least mitigate the conditions or events that raise substantial doubt, and (iv)ifthe latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s abilitytocontinue as a going concern. These changes became effective for the Company for the 2017 annual period. The adoption of these changes did nothavea material impact on the financial statements.

In February 2016, the FASB issued ASU 2016-02,Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In March 2016, the FASB issuedASU2016-09,ImprovementstoEmployee Share-Based Payment Accounting. ThisASUaffects entities that issue share-based payment awards to their employees. TheASUis designed to simplify several aspects of accounting for share-based payment award transactions which include – the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations.ASU2016-09 will become effective for the Companyinthe first quarter of fiscal 2018. Early adoptionispermittedinany interim or annual period. The Companyiscurrently evaluating the impact of this guidance on its consolidated financial statements.

In April 2016, the FASB issued AS 2016-10, Revenue from Contracts with Customers (Topic 606), which amends certain aspects of the Board’s new revenue standard, ASU 2014-09, Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU 2014-09 which is effective for annual and interim periods beginning after December 15, 2017. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this updatewe do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is currently assessing the potential impact of adopting ASU 2017-11 on its financial statements and related disclosures.

3. ACCRUED EXPENSES

During 2003, the Company paid payroll net of taxesandaccrued said taxes without payment due to cash flow limitations resultingfroma2002warehouse fire that incinerated our inventory. The Company subsequently received a tax lien in 2005 related to 2003 payroll taxes from the Internal Revenue Serviceandcontinued to accrue interestandpenalty charges. The original amount was $104,052. In 2008, payments were made and the Internal Revenue Service issued a tax lien release for this amount and the liability carried on the Company’s books was relieved. In 2009, the Company was notified by the Internal Revenue Service that additional payroll taxes, interest, and penalty charges were still owed. After researching,consider it is believed that the Internal Revenue Service double booked the original payments made and releasedthelieninerror. Settlement was reached and the Companyiscurrently paying $2,578 per month on a total liability of $24,474 as of September 30, 2017, including interest. The Company recognized a reduction of accrued liability of approximately $200,000 relating to the settlement with the Internal Revenue Service, which was recorded as other income in 2016. This agreement will cure any default of the Company’s plan payments. The final payment is due on April 16, 2018.

4. INCOME TAXES

The Company’s book lossesandother timing differences resultina net deferred income tax benefit which is offset by a valuation allowance for anetdeferred asset of zero. The Company has concluded,inaccordance with the applicable accounting standards, thatit ismore likely than not that the Company may not realize the benefit of all of its deferreda future tax assets. Accordingly, management has providedasset will be recovered, we will provide a 100% valuation allowance against its deferredthe excess.

We follow the provisions of ASC 740, Income Taxes. Because of ASC 740, we make a comprehensive review of our portfolio of tax assets untilsuchtime as management believes thatitsprojections of future profits aswellas expected future tax rates make the realization of these deferred tax assets more-likely-than-not. Significant judgment is required in the evaluation of deferred tax benefits and differencesinfuture results from our estimates could resultinmaterial differencesinthe realization of these assets. The Company has recorded a full valuation allowance related toallof its deferred tax assets. The Company has performed an assessment of positive and negative evidence regarding the realization of the net deferred tax assetpositions in accordance with FASBrecognition standards established by ASC 740-10, “Accounting for Income Taxes.” This assessment included740.

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the evaluation of scheduled reversals of deferred tax liabilities,taxing authorities, while others are subject to uncertainty about the availability of carry forwardsandestimates of projected future taxable income. The availabilitymerits of the Company’s net operating loss carry forwards is subjecttolimitationifthereisa 50%position taken or more changeinthe ownershipamount of the Company’s stock.position that would be ultimately sustained. The provision for income taxes consists of the state minimum tax imposed on corporations of $800. The Company has adopted guidance issued by the FASB that clarifies the accountingforuncertainty in income taxes recognized inanenterprise’s financial statements and prescribes a recognition threshold of more likely than not and a measurement processforfinancial statement recognition and measurementbenefit of a tax position taken or expected to be takenis recognized ina tax return. In making this assessment, a company must determine whether our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that a taxthe position will be sustained upon examination, based solely onincluding the technical meritsresolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the position and must assumebenefits associated with tax positions taken that exceeds the tax position will be examinedbytaxing authorities.TheCompany’s policyamount measured as described above istoinclude interestandpenalties relatedto reflected as a liability for unrecognized tax benefits in incomethe accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

We have created our tax expense.provision leveraging known tax court cases involving various marijuana dispensaries and other cannabis related businesses, including the section of the IRS Tax code of 280E. The Company hasU.S. Tax Code Section 280E is the federal statute that states that a business engaging in the trafficking of a Schedule I or II controlled substance, which includes cannabis and cannabis related products, are barred from taking the tax deductions or credits in their federal tax returns which are not recognized anyconsidered as part of the business’ cost of goods sold. Given the guidance offered by the Tax code 280E we have prepared our tax provision according to this tax code.

13

Interest and penalties associated with unrecognized tax benefits, anddoesnothaveif any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations.

On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no significant impact on our income taxes for the nine months ended September 30, 2022 and 2021, respectively.

Research and Development Expenses– Research and development (“R&D”) costs are charged to expense as incurred. Our R&D expenses include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.

General and Administrative Expenses– General and administrative expenses consist primarily of personnel-related costs, fees for professional and consulting services, travel costs, rent, bad debt expense, general corporate costs, and other costs of administration such as human resources, finance and administrative roles.

Commitments and Contingencies – Certain conditions may exist as of the date our financial statements are issued, which may result in a loss, but which will only be resolved when one or penaltiesmore future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies relatedtouncertain tax positions legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

Net Loss Per Share – We compute net loss per share in accordance with ASC 260, Earnings per Share. Under the provisions of ASC 260, basic net loss per share includes no dilution and is computed by dividing the net loss available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share takes into consideration shares of common stock outstanding (computed under basic net loss per share) and potentially dilutive securities that are not anti-dilutive.

Cash and Cash Equivalents– The Company considers all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash equivalents. Cash equivalents may be invested in money market funds, certificates of deposit or other interest-bearing accounts.

Concentration of Credit Risk – Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may not be insured by the FDIC.

Accounts Receivable and RevenueThe accounts receivable balance was $22,977 as of September 30, 2017.2022 and $278,422 as of December 31, 2021. As of September 30, 2022, 100% of accounts receivable consisted of one customer and the remaining accounts receivable was determined to be uncollectible. During the three months ended September 30, 2022, 35% of the sales came from Summit Boys product third party sellers, 36% came from online sales, and the remainder of the sales was distributed between all other customers. During the three months ended September 30, 2021, we diversified our customer base, but still have 30% of the revenues from one customer.

14

We periodically review the value of our accounts receivable and provide an allowance for doubtful accounts based on our assessment of the age of the receivable and its collectability. During the nine months ended September 30, 2022, the Company reviewed the accounts receivable and based on the aging and likelihood of collectability, an allowance for doubtful accounts was created in the amount of $250,054. Any allowance is charged to general and administrative expenses.

Recently Issued Accounting Pronouncements – From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of an Accounting Standards Update (“ASU”). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our condensed consolidated financial statements upon adoption.

Recently Issued Accounting Pronouncements Not Yet Adopted

In March 2022, the FASB issued ASU 2022-02, Financial Instruments – Credit Losses (Topic 326) (“ASU No. 2022-02”). ASU No. 2022-02 eliminates the existing troubled debt restructuring recognition and measurement guidance, and instead aligns the accounting treatment to that of other loan modifications. The amendments enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. ASU No. 2022-02 also requires that entities disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases. ASU No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and is to be adopted prospectively. The Company does not expect the adoption of ASU No. 2022-02 to have a material impact on its condensed consolidated financial statements.

In May 2021, the FASB issued ASU 2021-04, Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2021-04”), which amends existing guidance for earnings per share (EPS) in accordance with Topic 260. ASU 2021-04 is effective for the Company beginning June 1, 2022. This update should be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.

Recently Issued Accounting Pronouncements Adopted

Convertible Debt, and Derivatives and Hedging In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 will be effective for the Company in the first quarter of 2022. The Company is currently evaluating the amended guidance and the impact on its consolidated financial statements and related disclosures.

15

NOTE 3 – GOING CONCERN

Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the nine months ended September 30, 2022, we incurred a net loss of $2,607,703, had a working capital deficit of $7,268,825 and had an accumulated deficit of $19,433,867 at September 30, 2022. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations as they come due. There is no assurance that these events will be satisfactorily completed. As a result, there is doubt about our ability to continue as a going concern for one year from the issuance date of these financial statements

Management’s plan regarding this matter is to, amongst other things, seek additional equity financing by selling our equity securities and obtaining funds through the issuance of debt. We cannot be certain that funds from these sources will be available when needed or, if available, will be on terms favorable to us or to our stockholders. If we raise additional funds or settle liabilities by issuing equity securities, the percentage ownership of our stockholders may be reduced, stockholders may experience additional dilution, or such equity securities may provide for rights, preferences and/or privileges senior to those of the holders of our common stock. Our ability to execute our business plan and continue as a going concern may be adversely affected if we are unable to raise additional capital or operate profitably.

NOTE 4 – RIGHT OF USE ASSET AND LIABILITY

We lease capital equipment in a suitable, compliant cannabis facility located in the city of Desert Hot Springs. In addition, we entered into this operating land lease agreement with Coachillin’ Holdings LLC on September 1, 2018 to rent approximately 2,268 square feet of leasable land area. The operating lease renews annually and has a base rent of $0.50 square foot of leasable area of the designated premise assigned by Coachillin’ Holdings LLC. We paid an initial non-refundable prepaid rent of $3,402 which was expensed during the three months following the signed agreement, and we will continue to pay $1,134 monthly.

The Company entered into a 18-month lease agreement for office space in July 2019 at $6,304 a month, with an approximate 3% increase annually.

The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental borrowing rate of 10% to estimate the present value of the right of use liability.

The Company has right-of-use assets of $102,475, right-of-use liability of $102,475 as of September 30, 2022. Operating lease expense for the nine months ended September 30, 2022 was $72,180.

The following table provides the maturities of lease liabilities at September 30, 2022:

SCHEDULE OF MATURITIES OF LEASE LIABILITIES

     
Maturity of Lease Liabilities    
2022  22,316 
2023  86,997 
2024  - 
2025  - 
2026  - 
2027 and thereafter  - 
Total future undiscounted lease payments  109,313 
Less: Interest  (6,838)
Present value of lease liabilities $102,475 

 

5.

16

NOTE 5 – INVENTORY

At September 30, 2022 and December 31, 2021, our inventory was, as follows:

SCHEDULE OF INVENTORY

  September 30, 2022  December 31, 2021 
Raw material $85,294  $84,951 
Work in process  20,000   - 
Finished goods  232,210   304,331 
Total inventory  $337,504  $389,282 

At September 30, 2022 and December 31, 2021, finished goods included $690 and $20,904 on consignment, respectively. In addition, some finished goods product needed to be reworked and is temporarily moved to work in process.

We periodically review the value of our inventory and provide a write-down of inventory based on our assessment of the market conditions. Any write-down is charged to cost of goods sold. When inspecting inventory this quarter, we found some inventory was damaged, which necessitated a $68,941 reduction in inventory. Most of the product was salvageable and will be ready for resale in November 2022.

NOTE 6 – PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment, net of accumulated depreciation and amortization, at September 30, 2022 and December 31, 2021 was as follows:

SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT, NET

  September 30, 2022  December 31, 2021 
Vehicle $41,142  $41,142 
Furniture and equipment  7,494   7,494 
Extraction equipment  302,636   302,636 
Extraction laboratory  126,707   126,707 
Warehouse facility  50,158   50,158 
Land and land improvement/development  1,505,012   1,505,012 
Accumulated depreciation and amortization  (322,510)  (263,522)
Property, plant, and equipment $1,710,639  $1,769,627 

The Company acquired the extraction equipment, laboratory, and warehouse facility during 2018 and 2019 and prepared and final testing for future production. Final preparations for certain extraction and warehouse work were completed, and these related assets were placed in service on April 1, 2019, at which time we commenced depreciating this asset.

The amount of related depreciation expense for the nine months ended September 30, 2022 and 2021 is $58,988 and $69,598, respectively.

NOTE 7 – CAPITAL LEASE PAYABLE

Capital lease payable consists of a capital lease agreement entered into in April 2018 to finance the purchase of various lab and manufacturing equipment. The outstanding balance on the 48-month installment capital lease was $0 and $8,822 as of September 30, 2022 and December 31, 2021, respectively. The terms of the 48-month capital lease specify monthly payments of $4,575. The interest rate implicit in the lease is about 15% and the maturity date was February 2022. The lease has been paid in full and we now retain ownership of the equipment.

In addition, the Company entered into additional 48-month leases in May 2019 for production facilities and storage of product. Monthly payments for the facility and storage totals $1,935.

A summary of minimum lease payments on capital lease payable for future years is as follows:

SUMMARY OF MINIMUM LEASE PAYMENTS ON CAPITAL LEASE

  September 30, 2022 
Remainder 2022 $5,805 
2023  7,740 
2024  - 
2025  - 
2026  - 
Thereafter  - 
Total minimum lease payments  13,545 
Less: amount representing interest  (197)
Capital lease liability $13,348 

17

NOTE 8 – NOTES PAYABLE

During 2015In October 2017, in connection with our purchase of two acres of fully entitled cannabis real property located in the Coachillin’ Industrial Cultivation and 2016,Ancillary Canna-Business Park, the Company issued promissory notesa first and second trust deed note in the aggregate amountamounts of $942,850$700,000 and $200,000, respectively. The first and second trust deed notes are long-term notes and are interest only notes, at 13.0%, and mature in August 2022, with the full principal payment due at maturity. For the $700,000 loan, the monthly interest payment is approximately $7,500. For the $200,000 loan, the monthly interest payment is approximately $2,200. Unpaid interest as of September 30, 2022 is $37,888 and $6,495, for cash proceeds of $872,500. These notes bear interest at 5%-10% per annumthe two loans respectively. The 1st and several were due on various dates throughout 2015 and 2016 and several are due in 2017. These notes2nd trust deeds are secured by substantially all assetsthe land as well as property owned by two officers of the Company.company and three other related parties. Also, each party has personally guaranteed or pledged additional collateral. The convertible promissory notes are convertible into sharesinclude a debt discount as of September 30, 2022 of $9,000. The Company plans to repay these notes with the Company’s common stock at a rate equalproceeds from the recapitalization disclosed in the “Binding Letter of Intent to $0.01-$0.05 per share, subject to downward adjustments for future equity issuances. Acquire Diagnostic Lab Corporation” in “Grapefruit’s Business Development” in Note 1.

In connection with these convertible promissory notes,April 2018, the Company issued warrantsa note due 60 days after funding to purchase 66,500,000 sharesan unrelated third party with a principal amount of common stock at$250,000 and immediate interest charge totaling $125,000. As of September 30, 2022, the note has not been repaid and was amended to carry an exercise price of $0.01 per share, subject to downward adjustments for future equity issuances. The warrants have a term of 7 years from the date of issuance. The Company is in default under the terms of these notes.

The conversion features and warrants are considered derivative liabilities pursuantto ASC815 and were measured at their grant-date fair value and recorded as a liability and note discount on the date of issuance. Subsequent changestothe valueadditional 10% interest rate of the derivative liabilities are recorded in earnings. As a result, during the year ended December 31, 2016,total balance due. Accrued interest for this loan totals $284,375. The note is past due. Two officers of the Company recordedhave personally guaranteed the loan.

In March and May 2022, the Company issued another note of $40,000 and $10,000, respectively, to an initial note discount of $455,000,unrelated party with10% interest, which will mature in 6 months. In October 2021, there was an additional immediate chargenote for $6,000. The unrelated party has notes totaling $56,000, all with similar terms. Each note as it matures will continue to accrue interest at the stated rate until repayment.

NOTE 9 – CONVERTIBLE NOTES PAYABLE

Amortization of note discounts, which is included in interest expense, of $749,809 relatingtothe excess value of the derivative liabilities over the promissory notes. Amortization of the note discount amounted to approximately $290,000$313,731 during the nine months ended September 30, 20172022 and $272,000$692,129 for the nine months ended September 30, 2016.2021.

Grapefruit acquired convertible notes in its acquisition of Imaging3, Inc. on July 10, 2019. (See Note 15.) On January 5, 2017May 31, 2019, the Company executed the SPA with Auctus pursuant to the terms of which the Company agreed to sell $4,000,000 of the Notes and issue $6,200,000 of callable warrants (the “Warrants” and, together with the Notes, the “Securities”) to Auctus. Auctus is the Selling Security Holder. In addition, on May 31, 2019, we also entered into a financing arrangementregistration rights agreement with five accredited investorsAuctus (the “Investors”“Registration Rights Agreement”), whereby amendmentswe are obligated tocertain convertible note agreements totaling $662,000 were enacted. The amendments file a registration statement to register the convertible note agreements involved(1)extending the maturity datesresale of the note agreements; and (2) amendingshares underlying the optional conversion provisionsSecurities. On July 25, 2019 (as amended on January 17, 2020), a registration statement was filed to comply with the Registration Rights Agreement. Pursuant to the SPA, Auctus became obligated to purchase the $4,000,000 of Notes from Grapefruit in four tranches as follows: $600,000 at the original note agreementstonow describe an adjustable conversion price basedSPA closing, which was funded on June 6, 2019; the second tranche of $1,422,750 on the completionday IGNG filed the registration statement, which was funded on August 16, 2019; the third tranche of a qualified$1,030,000 was funded the day the SEC declares the registration statement effective and the fourth tranche of $1 million was funded 90 days after effectiveness. As of December 31, 2020, all tranches of this financing offering. If the cumulativewere completed. The Company has received gross proceeds of such offerings exceed $2.5 million,theconversionprice$4,052,750. The Notes have a two-year term and will be adjusted automaticallytomatchbear interest at 10%, with a default interest rate of 24%. As of September 30, 2022, three notes are in default.

On April 15, 2021, the offering’scompany renegotiated the debt agreement related to these notes modifying the convertible notes conversion price and conversionfrom a variable rate tocommon shares will occur automatically. If the cumulative gross proceeds of such offerings remain below $2.5 million, the a fixed rate conversion price adjusts to matchof $0.075 per share with an effective date of December 31, 2021. As a result of the offering conversion priceagreement, the Company recorded a noncash expense for the Investors. Should there be an event of default under these amended notes, the Investors will have,inadditiontoall the other rights describedinthat certain Securities Purchaser Agreement, the right, at each Investor’s option, to convert the notes into common shares at $0.01 per share. The Company and certain Investors agreedtoamend its warrant agreements to reduce the number of warrants by 75%to16,625,000. The exercise price remains at $0.01 per share. In consideration of this reduction of the number of warrants, the Company issued to the Investors new convertible promissory notesintotal principal amount of $124,688change in the same form asvalue of derivative instruments of $40,372,883, which was simultaneously offset by a noncash gain of $39,640,477 from the original convertible notes described above as amended. These additional convertible notes accrue interest beginning on January 9, 2017 and are due May 18, 2018.

The amendment to the notes and warrants were accounted for as an extinguishment of debt, resulting a net loss of $732,406 from the renegotiation of the debt.

18

On February 26, 2021, the company issued a convertible note for $450,000. The note has an interest rate of 10% and matures in 12 months. Note is currently in default with no updated maturity date. The note continues to accrue interest, which resulted in a gain on extinguishmenthas an accrued interest balance of debt totaling $3,668,776 for the nine months ended September 30, 2017. The outstanding derivative liability relating to the amended notes and warrants was approximately $86,930$87,150 as of September 30, 2017.2022. This note was included in the amendment making it convertible at $0.075 per share.

On June 22, 2022, Auctus converted $1,200,000 of convertible notes and $545,818 of accrued interest at the fixed rate of $0.075 for 23,277,573 shares.

 

On September 1, 2022, the company issued a convertible note for $104,250. The Investors agreednote has an interest rate of 8% and matures in 12 months. After 180 days, the note holder has the option of converting the note. The conversion price is 65% of the lowest trading price 10 days prior to lendthe date of conversion.

In addition, the Company up to $200,000, in increments of $50,000, at the Company’s discretion (the “Additional Loans”), as long as the Original Noteshas eleven other convertible notes comprising $296,000 outstanding and they are notcurrently in default. These loans will be evidenced by note agreementsThe interest on these notes varies from 5-10%. We are in the process of converting eight of the notes amounting to $241,000.

SCHEDULE OF CONVERTIBLE NOTES

December 31, 2021 Balance $3,966,048 
Additional notes  104,250 
Note conversions/repayment  (1,200,000)
Note discount  (115,608)
September 30, 2022 Balance $2,754,690 

NOTE 10 – NOTES PAYABLE, RELATED PARTY NOTES PAYABLES, AND OPERATING LEASE – RELATED PARTY

Notes payable to officers and directors as of September 30, 2022 and December 31, 2021 are due on demand and consisted of the following:

SCHEDULE OF NOTES PAYABLE TO OFFICERS AND DIRECTORS

  September 30, 2022  December 31, 2021 
Payable to an officer and director $1,000,653  $528,404 
Payable to an individual affiliate of an officer and director  270,120   47,560 
Payable to a company affiliate to an officer and director  194,424   126,617 
Notes payable to officers and directors $1,465,197  $702,581 

Notes payables bear interest at 10%.

A related party leased two eco-pods in April 2019 and May 2019, which are refurbished shipping containers, located on this specific parcel within Coachillin’. The lease is treated as an operating lease and payment responsibility is ultimately the responsibility of the related party. The Company assumed these lease payment obligations in May 2019. The monthly payments are $1,055 and $880, for the duration of the lease terms of four and five years, respectively.

On May 17, 2021, related parties converted $699,236 of principal and accrued interest, a total of 11,710,465 shares of common stock.

For the nine months ending September 30, 2022, payables to related parties came in the form of the original notes as amended, described above, withunpaid salary to executives, $450,000; and cash loans and direct payment to vendors, $320,751. In addition, there was a maturity daterepayment of May 18, 2018 and bear interest at 10% per annum. These notes have a face valueprincipal of 118.75%$8,135 to one of the funds actually advanced and contain conversion features (conversion pricerelated parties.

NOTE 11 – EQUITY

Preferred Stock

The Company has authorized 1,000,000 shares of $0.025 per share) making them derivative instruments.$0.0001 par value preferred stock. As of September 30, 2017, $150,034 of cash proceeds have been received from this agreement, for a total principal outstanding of $178,166. The Additional Loans2022, and December 31, 2021, there are secured by a UCC filing on the Company’s assets. In connection with these note agreements, the derivative liability created by these note agreements and warrants totaled $288,057. The derivative liability in excess of the cash proceeds received was recorded as a charge to interest expense, which totaled $136,835. In addition, the Company issued 3,750,000 warrants in the form of the original Warrants as amended granting the Investor the right to purchase, at $0.01 per share in connection with these notes.

The outstanding derivative liability relating to the Additional Loans and the related warrants is $23,173 as of September 30, 2017.

The agreement to amend the notes and warrants and to loan additional monies to the Company, as described above, was dependent on the two officers of the Company—Chief Executive Officer Dane Medley and Chief Financial Officer Xavier Aguilera—agreeing to restate their respective employment agreement, which they both have done.

On January 10, 2017, certain note holders converted notes to common shares. The total principal and accrued interest balance converted amounted to $196,797. The conversion resulted in the issuance of 8,627,500 common shares. The fair market value of the common shares on the date of conversion totaled $431,375.

On May 25, 2017 the Company completed the sale of $500,000 of Convertible Promissory Notes (the “Notes“) to two accredited investors (the “Investors”) that are due May 23, 2018 (the “Maturity Date”). After transaction costs, the company netted $425,000 from the sale of the Notes.

These Notes bear interest at the rate of 12% per annum to the Maturity Date and may be redeemed by the Company for 125% of face value within 90 days of issuance and at 135% of face value from 91 days after issuance and before 180 days after issuance. Any amount of principal or interest on these notes which is not paid when due shall bear interest at the rate of 24% per annum from the due date thereof until the same is paid.

If the Notes are not repaid by the end of this period, any balance due is convertible—at the option of the note holders—into common stock at 60% of the lowest closing price for the prior 20 trading days.

In connection with the sale of the Notes, the Investors received a commitment fee totaling 18 million shares valued at $180,000, and the holders of a majority of the principal amount of the Company’s notes outstanding at May 18, 2017 (the “Prior Notes”) executed, as of that date, an Omnibus Amendment that enabled the transaction by (i) extending the maturity date of these Prior Notes to May 18, 2018 and (ii) restricting the rights of all the holders of the Prior Notes, including their right to convert until certain conditions are met. In addition, the holders of these Prior Notes were relieved of their obligation to provide the final note tranche of $50,000.

6. STOCKHOLDERS’ EQUITY Preferred Stock

Upon confirmation of the Company’s Chapter 11 Reorganization Plan, the Company is authorized to issue 2,000no shares of preferred stock no par value. The rights, privileges, and preferences of the preferred stock are to be determined by the Company’s board of directors and may be issuedinseries.Asof January 18, 2016, Imaging3 issued 2,000 preferred voting sharestoDane Medley, CEO/Chairman. Each share constitutes 350,000 voting shares. The estimated value of these shares was not significant. However, Dane Medley relinquished these voting shares during the first quarter ended March 31, 2017 for consideration of $60,000, which has not yet been paid.outstanding.

19

 

Common Stock

The Company is authorized to issue 1,000,000,000 shares of no$0.0001 par value common stock.

During the nine months ended September 30, 2016,2022 the companyCompany issued a total of 4,364,00024,025,354 shares of common stock for cash proceeds of $159,900 and 32,000,000 shares of common stock for services rendered valued at $1,612,500.$473,890; 2,325,878 shares were issued related to legal settlement valued at $47,039; 23,277,573 shares were issued for the conversion of notes and accrued interest.

During the nine months ended September 30, 20172021 the Company issued a total of 150,0007,449,937 shares of common stock for cash in the amount of $7,000 and 50,830,000 shares were issued for services rendered valued at $648,300.$303,544; 20,114,651 shares were issued related to legal settlement and debt settlement with related parties valued at $2,281,695; 13,352,264 shares were issued related to the conversion of convertible notes valued at $996,620; 1,000,000 shares were issued for a stock purchase valued at $0.075 per share; 2,000,000 shares were issued for warrant exercised at $0.125 per share; and 4,545,455 shares were issued for the Summit Boys acquisition valued at $250,000.

As of October 19, 2017,September 30, 2022, there were approximately 8,375610 record holders of our common stock, not including shares held in “street name” in brokerage accounts the number of which is unknown. As of September 30, 2017,2022, there were 309,313,065606,791,549 shares of our common stock outstanding on record.

Stock Option Plan

During 2014, the Board of Directors adopted, and the shareholders approved, the 2014 Stock Option Plan under which a total of 27,000,0001,811,401 shares of common stock had been reserved for issuance. The 2014 Stock Option Plan will terminate in September 2024.2024.

Stock Options

As of September 30, 2017,2022, employees of the Company hold options to purchase 5,000,000250,000 shares of common stock granted in 2016 at an exercise price of $1.00. On March 28, 2021, the Company granted a board member an option to purchase 750,000 shares of common stock at an exercise price$0.025. There are nine month vesting periods for a block of250,000 shares starting October 1, 2021.

$0.025. On September 15,2017, two officers exercised their 8,000,000 options at a cost of $200,000, by offsetting and reducing their deferred salary and other amounts owed to them by the Company.SCHEDULE OF STOCK OPTIONS ACTIVITY

Transactions in FY 2022 Quantity  Weighted-Average Exercise Price
Per Share
  Weighted-Average Remaining Contractual Life 
Outstanding, December 31, 2021  250,000  $1.00   2.82 
Granted  750,000  $0.025   4.51 
Exercised  -         
Cancelled/Forfeited  -         
Outstanding, September 30, 2022  1,000,000  $0.27   4.08 
Exercisable, September 30, 2022  750,000  $0.35   3.78 

     Weighted-
Average
  Weighted-
Average
Remaining
 
Transactions in FY 2017 Quantity  Exercise Price
Per Share
  Contractual
Life
 
Outstanding, December 31, 2016  13,000,000  $0.025   8.61 
Granted  0         
Exercised  (8,000,000)        
Cancelled/Forfeited  0         
Outstanding ,September 30, 2017  5,000,000  $0.025   8.00 
Exercisable, September 30, 2017  5,000,000  $0.025   8.00 

The weighted average remaining contractual life of options outstanding issued under the Planagreements was 8.004.08 years at September 30, 2017.2022.

In April 2017, the Company cancelled 28 million shares of common stock held by officers.NOTE 12 — WARRANTS

7. WARRANTS

Following is a summary of warrants outstanding at September 30, 2017:2022:

SUMMARY OF WARRANTS OUTSTANDING

Number of Warrants  Exercise Price  Expiration Date
 575,000   0.10  Apr-23
 125,000   0.10  May-23
 162,500   0.10  Aug-23
 302,776   0.10  Jan-24
 14,000,000   0.125  May-24
 15,000,000   0.15  May-24
 8,000,000   0.25  May-24
 20,000,000   0.075  Apr-26
 2,250,000   0.20  Feb-26

20

 

Number of      
Warrants  Exercise Price  Expiration Date
 10,827,224  $0.000001  July 2023
 500,000  $0.01  April 2022
 6,250,000  $0.01  August 2022
 5,750,000  $0.01  April 2023
 2,500,000  $0.01  May 2023
 1,625,000  $0.01  August 2023
 56,000,000  $0.02  May 2022
 3,750,000  $0.01  January 2024

Effective May 1, 2017, the BoardGrapefruit recorded warrants to issue common stock upon exercise in its acquisition of DirectorsImaging3, Inc. on July 10, 2019. As part of the SEA, the Company authorized the issuance of 56,000,000also issued 16,000,000 warrants to purchase 56,000,00016,000,000 shares of the Company’s common stock at an exercise price of $0.02$0.125 per share, 15,000,000 warrants to purchase 15,000,000 shares of the Company’s common stock at an exercise price of $0.15 per share, 8,000,000 warrants to purchase 8,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share for a period of five yearstwo year from the date of issuanceissuance. (See Note 9)

In addition to the officersNotes in connection with the SPA agreement, GPFT issued to the Investor a warrant to purchase 16,000,000 shares of its common stock at $0.125 per share, a warrant to purchase 15,000,000 shares at $0.15 per share and a warrant to purchase 8,000,000 shares at $0.25 per share (collectively, the “Warrants”). The Warrants are “cash only” and are callable if GPFT stock trades on the OTCQB at 200% or more of the Company. Thesegiven exercise price for 5 consecutive days.

On February 26, 2021, 2,250,000 warrants were fully-vested upon grant andissue with an exercise price of $0.125 in relation to the convertible note (See Note 9 Convertible note payable). On April 15, 2021 as such, an expense was recognized upon grant. The fair valuepart of the renegotiated terms of the convertible notes, 20,000,000 additional warrants was calculated using a Black-Scholes model and was estimated to be $194,956. The significant assumptions used in the calculations were as follows:issued at an exercise price of $0.075.

Term5.0 years
Dividend Yield0%
Risk-free rate1.84%
Volatility60%

8. NOTE 13 — DERIVATIVE LIABILITIES

Grapefruit recorded derivative instruments in its acquisition of Imaging3, Inc. on July 10, 2019. (See Note 15.) The Company’s only asset or liability measured at fair value on a recurring basis was its derivative liability associated with related warrants to purchase common stock and the conversion featurefeatures embedded in convertible promissory notes.

In connection with previous financing transactions, the Company issued warrantstopurchase common stock and convertible promissory notes. These instruments included provisions that could result in a reduced exercise price based on specified full-ratchet anti-dilution provisions. The “reset” provisions were triggered in the event the Company subsequently issued common stock, stock warrants, stock options or convertible debt with a stock price, exercise price or conversion price lower than contractually specified amounts. Upon triggering the “reset” provisions, the exercise / conversion price of the instrument will be reduced. Accordingly, pursuantto ASC815, these instruments were not consideredtobe solely indexed totheCompany’s own stock and were not afforded equity treatment.

On April 15, 2021, the company renegotiated conversion terms on $4,502,750 of convertible notes with Auctus. All variable conversion prices were replaced with a fixed conversion price of $0.075. In addition, the Company issued an additional 20,000,000 warrants with an exercise price of $0.075 per share.

On September 1, 2022, with the issuance of the convertible note mentioned in Note 9 – Convertible Notes Payable, a new derivative was created and will be tracked for the life of the note.

The following table summarizes activity in the Company’s derivative liability during the nine monthsnine-month month period ended September 30, 2017:2022:

SUMMARY OF DERIVATIVE LIABILITY

     
December 31, 2021 Balance $127,392 
Creation/acquisition  133,654 
Reclassification of equity  - 
Change in Value  (138,081)
September 30, 2022 Balance $122,965 

21

 

12-31-2016 Balance $5,532,898 
Creation $416,205 
Reclassification to equity $(163,674)
Change in Value and Extinguishment of Debt $(5,674,923)
09-30-2017 Balance $110,506 

The Company classifies the fair value of these derivative liabilities under level 3 of the fair value hierarchy of financial instruments. The fair value of the derivative liability was calculated using a Black-ScholesBinomial Tree model. The Company’s stock price and estimates of volatility are the most sensitive inputs in validation of assets and liabilities at fair value. The liabilities were measured using the following assumptions:

SCHEDULE OF ASSUMPTIONS USED

Term  0.5 years 0- 7.0 years1 year 
Dividend Yield  0%
Risk-free rate  1.20%1.72% - 1.77%4.05%
Volatility  60150-160%

9.

NOTE 14 – SEGMENT INFORMATION

Segment reporting is prepared on the same basis that the Company’s Chief Executive Officer, who is the Company’s Chief Operating Decision Maker, manages the business, makes operating decisions and assesses performance.

As of September 30, 2022 the Company’s two segments are as follows:

SegmentDescription
RetailThe retail segment includes products sold through our online stores and third-party sales teams.
WholesaleThe wholesale segment includes products sold to our preexisting and newly acquired customers.

The majority of costs are run through the wholesale segment, which includes the fixed costs associated with production of inventory. The Company has begun to promote sales of Summit Boys branded product, which is primarily sold direct to consumer, and felt is necessary to differentiate between the two segments. Segment information is summarized below:

SCHEDULE OF SEGMENT INFORMATION

  Three months
ended
  Three months
ended
  Nine months
ended
  Nine months
ended
 
  September 30, 2022  September 30, 2021  September 30, 2022  September 30, 2021 
Revenue                
Retail $2,087  $3,705  $25,655  $7,838 
Wholesale  875   149,771   7,018   578,942 
Revenue $2,962  $153,476  $32,673  $586,780 
                 
Gross margin                
Retail $620  $728  $3,023  $3,234 
Wholesale  (61,588)  (198,483)  (274,164)  (352,899)
Gross margin $(60,968) $(197,755) $(271,141) $(349,665)

NOTE 15 – INVESTMENTS

Investment in Hemp

In September 2019, the Company invested in hemp product that was purchased and stored by a third party. The Company expects to sell the product by the beginning of next year. Due to the increased harvests, the salability of the product decreased, necessitating the complete mark down, which occurred in 2021.

NOTE 16 – COMMITMENTS AND CONTINGENCIES

Mentor Group, Inc. vs Imaging3, Inc. Settlement

On March 8, 2022, Grapefruit USA, Inc. was contacted by an attorney about outstanding litigation between Mentor Group, Inc. and Imagaing3, Inc. The settlement was for $27,593 of past debt, $8,869 in attorney fees, and $3,644 of interest. Currently no payment plan is in place. This debt is related Imaging3, Inc.’s prior business activities which preceded Grapefruit’s acquisition of Imaging3, Inc., and was inherited or assumed by Grapefruit. As of September 30, 2022, the Company is still continuing to make payments.

22

 

Galileo Surgery Center LP/Cypress Ambulatory Surgery Center LP vs Imaging3, Inc. Settlement

The Company came to a settlement with Galileo Surgery Center LP/Cypress Ambulatory Surgery Center LP (“Galileo”) for $75,572 with an interest rate of 10%, requiring payments of $7,300 per month beginning in August 2021 until paid in full. This debt is related Imaging3, Inc.’s prior business activities which preceded Grapefruit’s acquisition of Imaging3, Inc., and was inherited or assumed by Grapefruit. As of September 30, 2022, the Company is still continuing to make payments.

Administrative Claim of Greenberg Glusker Fields Claman & Machtinger LLP

On JanuaryThe Company came to a settlement agreement with Greenberg Glusker Fields Claman & Machtinger LLP (“Greenberg”). Three $68,000 payments are to be made in relation to the timing of the three latter tranches mentioned in “Auctus Financing” or before November 30, 20172019. As of now, $68,000 has been paid; late penalties are currently being assessed. In addition, 7,628,567 shares are to be issued as part of the settlement agreement—7,213,933 of the shares were issued as of September 30, 2022. In May 2021, the Company entered into a new Agreement. Under the termsissued 3,920,865 shares as part of the Agreement,make-whole clause in the agreement. On October 26, 2021, the Company has agreed to pay Greenberg $1,117,574 plus any interest that has accrued at the rate of 6.0% per annum,issued 600,000 shares as follows: (i) $100,000 on or before December 31, 2017; (ii) $150,000 on or before December 31, 2018 (iii) 4.0%part of the first $2.5 millionmake-whole clause in the agreement. Additional shares may need to be issued in the future. This debt is related Imaging3, Inc.’s prior financing activities which preceded Grapefruit’s acquisition of gross proceedsImaging3, Inc., and was ‘inherited’ or ‘assumed’ by Grapefruit.

NOTE 17 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the filing of any private or public offering by the company (an “Offering”); (iv) 2.0% of the next $2.5 million of gross proceeds from such Offerings; (v) 4.0% of any gross proceeds thereafter from such Offerings;this Quarterly Report on Form 10Q and (vi) the remaining balance on or before December 31, 2019.

In addition, Greenberg has the option to convert up to $150,000 of the balance into a warrantdetermined that there have been no events that have occurred that would convert on terms that are equalrequire adjustments to (or, in certain cases, better than) the terms offered in subsequent rounds of financing.

Bankruptcy Closure

On January 31, 2017, United States Bankruptcy Judge for the Central District of California, Neil Bason, granted the company’s unopposed motion for entry of final decree and also granted approval of the two stipulations regarding payment of court-approved fees. The Company noted that as a result, the Imaging3 Chapter 11 proceeding is now closed—the company is no longer subject to the jurisdiction of the Bankruptcy Court, and the case cannot be converted to a Chapter 7 proceeding.

Toclarify, the Judge’s orderinits final paragraph stated that “Notwithstanding the foregoing [order closingthebankruptcy case pursuant to 11United States Code Section 350(a)] the bankruptcy case may be reopened on motionasset forthour disclosures in the Greenberg, Glusker Fee Agreement and/or the Mentor Fee Agreement and thus the court retains jurisdiction for those purposes and as otherwise provided by law or as contemplated by the prior orders and proceedings of this court”. Thusly, technically, the case could possibly be reopened by either of those aforementioned creditors.financial statements.

23

 

Pending Litigation

On September 13, 2017 Alpha Capital Anstalt and Brio Capital Master Fund, LTD two minority members of a group of investors in the Company filed a lawsuit seeking damages and injunctive relief in the United States District Court for the Southern District of New York claiming that the Company breached certain Note and Warrant agreements among the parties to the action. The holders of the majority of the investment involved in the above lawsuit chose not to join in the lawsuit and have informed the Company that they believe the lawsuit to be baseless. The Company believes the lawsuit is without merit and is aggressively defending against it. The litigation is currently in its preliminary pleading stage and the Company is seeking to have the injunctive counts of the lawsuit dismissed for failure to state a cause of action.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Statements

This Form 10-Q may containcontains financial projections and other “forward-looking statements,” as that term is used in federal securities laws, about Imaging3, Inc.’sGrapefruit’s financial condition, results of operations and business. These statements include, among others:others, statements concerning the potential for revenues and expenses and other matters that are not historical facts. These statements may be made expressly in this Form 10-K. You can find many of these statements by looking for words such as “believes,” “expects,” “anticipates,” “estimates,” or similar expressions used in this Form 10-K. These forward-looking statements are subject to numerous assumptions, risks and uncertainties that may cause our actual results to be materially different from any future results expressed or implied by us in those statements. The most important facts that could prevent us from achieving our stated goals include, but are not limited to, the following:

statements concerning the potential benefits that Imaging3, Inc. (“Imaging3” or the “Company”) may experience from its business activities and certain transactions it contemplates or has completed; and
(a)
statements of Imaging3’s expectations, beliefs, future plans and strategies, anticipated developments and other matters that are not historical facts. These statements may be made expressly in this Form 10-Q. You can find many of these statements by looking for words such as “believes,” “expects,” “anticipates,” “estimates,” “opines,” or similar expressions used in this Form 10-Q. These forward-looking statements are subject to numerous assumptions, risks and uncertainties that may cause Imaging3’s actual results to be materially different from any future results expressed or implied by Imaging3 in those statements. The most important facts that could prevent Imaging3 from achieving its stated goals include, but are not limited to, the following:

(a)volatility or decline of Imaging3’sour stock price;
(b)potential fluctuation in quarterly results;
(c)our failure of Imaging3 to earn revenues or profits;
(d)inadequate capital to continue or expand itsthe business inabilityand barriers to raiseraising the additional capital or to obtaining the financing needed to implement itsour business plans;
(e)failure to commercialize Imaging3’s technology or to make sales;
(f)changes in demand for Imaging3’sour products and services;
(g)rapid and significant changes in markets;
(h)litigation with or legal claims and allegations by outside parties;parties, causing us to incur substantial losses and expenses;
(i)insufficient revenues to cover operating costs, resulting in persistent losses;costs;
(j)dilution in the ownership of the Company through the issuance by us of additional securities and the conversion of outstanding warrants, notes and other securities; and
(k)failure of Imaging3 to obtain approval of its proprietary medical imaging technology and device from the Federal Food and Drug Administration.

There is no assurance

24

We cannot assure that Imaging3we will be profitable. Imaging3We may not be able to successfully develop, manage or market itsour products and services. Imaging3services successfully. We may not be able to attract or retain qualified executives and technology personnel. Imaging3We may not be able to obtain customers for itsour products or services. Imaging3’sOur products and services may become obsolete. Government regulation may hinder Imaging3’sour business. Imaging3 may not be able to obtain the required approvals from the United States Food and Drug Administration for its products and services. Additional dilution in outstanding stock ownership maywill be incurred due to the issuance or exercise of more shares, warrants and stock options, or the exercise of outstanding warrants and stock options, or the conversion of notes. Imaging3 is exposed to other risks inherent in its businesses.convertible securities.

Because the statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by the forward-looking statements. Imaging3 cautionsWe caution you not to place undue reliance on the statements, which speak only as of the date of this Form 10-Q. The cautionary statements contained or referred to in this section should be considered in connection with any subsequent written or oral forward-looking statements that Imaging3we or persons acting on itsour behalf may issue. Imaging3 doesmake. We do not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

Current Overview

Though our efforts have been to market our refurbished equipment, a significant portion of our sales and revenues derive from services and the sale of parts, either from extended warranty purchases at the time of purchase of the refurbished equipment, or service contracts and time and material revenue realized upon warranty expiration, the majority of which is realized one year from equipment purchase as warranties expire.

Our sales effort through direct mail, broadcast facsimile and broadcast email to thousands of potential customers throughout the United States generates leads of potential customers desiring to purchase equipment either immediately orThe following discussion should be read in the course of one year. This lead generation through direct mail, broadcast and email will continue on a quarterly basisconjunction with the goal of increasing the total number of our leads for our sales staff. Management expects that the marketing program will also eventually help stabilize the company.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements which have been preparedand notes to those statements. In addition to historical information, the following discussion and other parts of this annual report contain forward-looking information that involves risks and uncertainties.

Results of Operations for the Three Months Ended September 30, 2022 as compared to the Three Months Ended September 30, 2021.

  Three months ended  Three months ended 
  September 30, 2022  September 30, 2021 
Net revenues $2,962  $153,476 
Cost of goods sold  62,758   346,073 
Gross income (loss)  (59,796)  (192,597)
Sales expense  1,172   3,800 
Stock based compensation  106,011   25,980 
Stock option expenses  6,008   32,877 
General and administrative expense  229,643   352,462 
Loss from operations  (402,630)  (607,716)
Change in value of derivatives  14,187   13,877 
Interest and other expense  (369,763)  (388,273)
Net loss before income taxes  (758,207)  (982,112)
Tax provision  -   - 
Net loss  (758,207)  (982,112)
Loss attributable to noncontrolling interest  -   (270)
Net loss attributable to Grapefruit USA, Inc. $(758,207) $(981,842)

The following sets forth selected items from our statements of operations for three months ended September 30, 2022 and for the three months ended September 30, 2021.

Revenue for the three months ended September 30, 2022 was $2,962 compared to $153,476 for the corresponding period in accordance with accounting principles generally accepted2021, a decrease of $150,514 or 98.1%. The decrease was primarily due to the decline of our distribution business caused by a combination of decreased demand for and an over-supply of cannabis flowers in the United States of America. The preparationCalifornia. As a result of these financial statements requiresmarket forces beyond our control we have severely limited our distribution operations and commenced the process of transitioning into a canna-biotech firm focusing on further developing and marketing of cannabis products based on our patented Hourglass Technology. On March 21, 2022, we received approval of our NNCP from Health Canada (NNCP ID No. NP-V2EHUWO907) which authorizes us to make estimatesmanufacture and judgments that affectsell our Hourglass™ products throughout Canada. As the reported amountsCompany expands marketing efforts, we anticipate to see additional growth.

25

Cost of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We monitor our estimates on an on-going basisgoods sold for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are recorded inthree months ended September 30, 2022 was $62,758 as compared to $346,073 for the corresponding period in which they become known. We base our estimates on historical experience2021, a decrease of $283,315, or 81.9%. Included in cost of goods sold are plant operation and other assumptions thatdirect overhead expenses incurred to maintain our production facilities. These fixed carrying costs affect our gross margin more significantly at lower revenues than at our anticipated full operating activity levels. When inspecting inventory this quarter, we believe tofound some inventory was damaged, which necessitated a $68,500 reduction in inventory. Most of the product was salvageable and will be reasonable underready for resale in November 2022.

Our resulting gross loss for the circumstances. Actual results may differ from our estimates if past experiencethree months ended September 30, 2022 was $59,796 as compared with the gross loss of $192,597 for the corresponding period in 2021, a decrease of $132,801, or other assumptions do not turn out to be substantially accurate.

We have identified69.0%. The decrease was a result of the policies below as critical to our business operationsgeneral decrease in sales and the understandingassociated costs of our resultsgoods sold.

Sales expense for the three months ended September 30, 2022 were $1,172 compared to $3,800 for 2021, decrease of operations.$2,628, or 69.2%. Stock based compensation for the three months ended September 30, 2022 were $106,011 compared to $25,980 for 2021, an increase of $80,031, or 308%. Stock option expenses for the three months ended September 30, 2022 were $6,008 compared to $32,877 for 2021, a decrease of $26,869, or 81.7%. General and administrative expenses for the three months ended September 30, 2022 were $229,643 compared to $352,462 for 2021, a decrease of $122,819, or 34.8%.

Revenue Recognition

Revenue is recognized upon shipment, provided that evidenceOur resulting net loss from operations for the three months ended September 30, 2022 was $402,630 as compared to $607,716 for the corresponding period for 2021, a decrease of an arrangement exists, title and risk$205,086, or 33,7%. Change in value of loss have passedderivatives gain for the three months ended September 30, 2022 was $14,187 as compared to the customer, fees are fixed$13,877 for 2021, a decrease of $310, or determinable and collection of the related receivable is reasonably assured. Revenue is recorded net of estimated product returns, which is based upon the Company’s return policy, sales agreements, management estimates of potential future product returns related to current period revenue, current economic trends, changes in customer composition and historical experience. The Company accrues for warranty costs, sales returns,2.2%. Interest and other allowances based on its experience. Generally,expense for the Company extends creditthree months ended September 30, 2022 was $369,763 as compared to its customers$388,273 for 2021, a decrease of $18,510, or 4.8%.

Net loss for the three months ended September 30, 2022 was $758,207 as compared to $982,112 for the corresponding period for 2021, a decrease of $223,905, or 22.8%. Loss attributable to noncontrolling interest for the three months ended September 30, 2022 was $0 as compared to $270 the corresponding period for 2021, a decrease of $270. Our resulting net loss attributable to Grapefruit USA, Inc. and does not require collateral. The Company performs ongoing credit evaluationssubsidiary for the three months ended September 30, 2022 was $758,207 as compared to $981,842 for the corresponding period for 2021, a decrease of its customers and historic credit losses have been within management’s expectations and has a revenue receivables policy for service and warranty contracts. Equipment sales usually have a one year warranty of parts and service. After a one year period, the Company contacts the buyer to initiate the sale of a new warranty contract for one year. Warranty revenues are deferred and recognized on a straight-line basis over the term of the contract$223,635, or as services are performed.22.8%.

Deferred Revenue

Deferred revenue consists substantially of amounts received from customers in advance of the Company’s performance service period. Deferred revenue is recognized as revenue on a systematic basis that is proportionate to the period that the underlying services are rendered, which in certain arrangements is straight-line over the remaining contractual term or estimated customer life of an agreement.

Research and Development

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, and overhead directly related to the Company’s research and development operations, as well as costs to acquire technology licenses.

Other Accounting Factors

The effects of inflation have not had a material impact on our operation, nor are they expected to in the immediate future.

Although we are unaware of any major seasonal aspect that would have a material effect on the financial condition or results of operations, the first quarter of each fiscal year is always a financial concern due to slow collections after the holidays.

Results of OperationOperations for the Nine Months Ended September 30, 2017 Compared2022 as compared to the Nine Months Ended September 30, 20162021.

  Nine months ended  Nine months ended 
  September 30, 2022  September 30, 2021 
Net revenues $32,673  $586,780 
Cost of goods sold  297,069   926,671 
Gross income (loss)  (264,396)  (339,891)
Sales expense  6,744   5,760 
Stock based compensation  301,916   265,024 
Stock option expenses  27,006   65,754 
General and administrative expense  974,685   1,011,199 
Loss from operations  (1,574,747)  (1,687,628)
Change in value of derivatives  138,081   91,210 
Interest and other expense  (1,171,036)  (2,149,021)
Net loss before income taxes  (2,607,702)  (3,745,439)
Tax provision  -   - 
Net loss  (2,607,702)  (3,745,439)
Loss attributable to noncontrolling interest  -   (270)
Net loss attributable to Grapefruit USA, Inc. $(2,607,702) $(3,745,169)

26

 

We had revenues in the first

The following sets forth selected items from our statements of operations for nine months of 2017 of $14,624ended September 30, 2022 and for the nine months ended September 30, 2021.

Revenue for the nine months ended September 30, 2022 was $32,673 compared to $40,393$586,780 for the corresponding period in 2016.2021, a decrease of $554,107 or 94.4%. The decrease in revenue iswas primarily due to the decline of our distribution business caused by a combination of decreased warranty sales.demand for and an over-supply of cannabis flowers in California. As a result of these market forces beyond our control we have severely limited our distribution operations and commenced the process of transitioning into a canna-biotech firm focusing on further developing and marketing of cannabis products based on our patented Hourglass Technology. On March 21, 2022, we received approval of our NNCP from Health Canada (NNCP ID No. NP-V2EHUWO907), which authorizes us to manufacture and sell our Hourglass™ products throughout Canada. As the Company expands marketing efforts, we anticipate to see additional growth.

Our costCost of revenue was $14,263 ingoods sold for the first nine months of 2017ended September 30, 2022 was $297,069 as compared to $10,247$926,671 for the corresponding period in 2016. The increase2021, a decrease of $629,602, or 67.9%. Included in cost of revenuegoods sold are plant operation and other direct overhead expenses incurred to maintain our production facilities. These fixed carrying costs affect our gross margin more significantly at lower revenues than at our anticipated full operating activity levels. When inspecting inventory this quarter, we found some inventory was damaged, which necessitated a $68,500 reduction in inventory. Most of the product was salvageable and will be ready for resale in November 2022.

Our resulting gross loss for the nine months ended September 30, 2022 was $264,396 as compared with the gross loss of $339,891 for the corresponding period in 2021, a decrease of $75,495, or 22.2%. The decrease was a result of outside laborthe general decrease in sales and the associated costs related to C-Arm repairs . We had a gross profit inof goods sold.

Sales expense for the first nine months of 2017 of $361ended September 30, 2022 was $6,744 compared to a gross profitthe $5,760 for 2021, an increase of $30,146 in$984, or 17.1%. Stock based compensation for the same period of 2016. Again, lack of sales had a direct impact on decreased gross profit margin. Our operating expenses decreased to $1,507,048 in the first nine months ended September 30, 2022 were $301,916 compared to $265,024 for 2021, an increase of 2017$36,892 or 13.9%. Stock option expenses for the nine months ended September 30, 2022 were $27,006 compared to $65,754 for 2021, a decrease of $38,748, or 58.9%. General and administrative expense for the nine months ended September 30, 2022 were $974,685 compared to $1,011,199 for 2021, a decrease of $36,514, or 3.6%.

Our resulting net loss from operations for the nine months ended September 30, 2022 was $1,574,747 as compared to operating costs$1,687,628 for the corresponding period for 2021, a decrease of $2,051,898$112,881, or 6.7%. Change in 2016, primarily as a resultvalue of stock based compensation activity. The loss from operations was $1,506,687 inderivatives gain for the first nine months of 2017 compared to a loss of $2,021,752 in 2016. Our net income was $3,341,377 in the first nine months of 2017 compared to a net loss of $6,116,611 in the first nine months of 2016, as a result of a derivative liability activity and gains on the extinguishment of debt.

Results of Operation for the Three Months Endedended September 30, 2017 Compared to the Three Months Ended September 30, 2016

We had revenues in the third quarter of 2017 of $4,946 compared to $23,195 in 2016. The decrease in revenue is due to decreased warranty sales.

Our cost of revenue2022 was $221 in the third quarter of 2017 compared to $1,905 in 2016. The decrease in cost of revenue was a result of diminished sales for the period. We had a gross profit in the third quarter of 2017 of $4,725 compared to a gross profit of $21,290 in the same period of 2016. Again, lack of sales had a direct impact on decreased gross profit margin. Our operating expenses increased to $652,178 in the third quarter of 2017$138,081 as compared to $417,845 in 2016, mainly due to stock based compensation activity in 2017. We had a loss from operations$91,210 for 2021, an increase of $647,453 in$46,871, or 51.4%. Interest and other expense for the third quarter of 2017nine months ended September 30, 2022 was $1,171,036 as compared to $2,149,021 for 2021, a decrease of $977,985, or 45.5%.

Net loss for the nine months ended September 30, 2022 was $2,607,702 as compared to $3,745,439 for the corresponding period for 2021, a decrease of $396,555 in 2016.$1,137,737, or 30.4%. Loss attributable to noncontrolling interest for the nine months ended September 30, 2022 was $0 as compared to $270 for the corresponding period for 2021, a decrease of $270. Our resulting net loss attributable to Grapefruit USA, Inc. and subsidiary for the nine months ended September 30, 2022 was $667,634 in the third quarter of 2017$2,607,702 as compared to $3,745,169 for the corresponding period for 2021, a net lossdecrease of $974,100 in the third quarter of 2016, as a result of derivative liability activity and stock based compensation during the 2016 period.$1,137,467, or 30.4%.

Liquidity and Capital Resources

The Company’sOur cash position was $26,079 at September 30, 2017, comparedincreased to $22,638 at December 31, 2016. The increase in September was due to proceeds received from the issuance of a new note payable.

As$23,583 as of September 30, 2017,2022 from $9,095 as of December 31, 2021. Our total current assets decreased to $644,496 as of September 30, 2021, from $714,199 as of December 31, 2021.

Our total current liabilities increased to $7,913,321 as of September 30, 2022 from $7,703,573 as of December 31, 2021.

27

During the Company has a working capital deficitnine months ended September 30, 2022, we used $317,552 of $2,192,228net cash for operating activities, as compared to $8,148,197 at December 31, 2016. This disparity was due primarily to a new agreement entered into with Greenberg Glusker Fields Claman & Machtinger LLP. (See Part II Other Information below for details),cash used by operations of $998,581 used during the settlement of debt in January 2017 and the resulting effect of the gain on extinguishment of debt.

nine months ended September 30, 2021. Net cash used in operatinginvesting activities amounted to $578,594 forduring the nine month periodmonths ended September 30, 2017,2022 was $0, as compared to net cash used in operating activities of $394,697 for$62,250 during the nine month periodmonths ended September 30, 2016 due primarily to the settlement of debt in January 2017 and the resulting effect of the gain on the extinguishment of debt.

2021. Net cash provided by financing activities amounted to $582,035 and $454,900 forduring the nine month periodsmonths ended September 30, 2017 and 2016, respectively. The increase in 20172022 was $332,040, as compared to 2016 resulted mainly from an increase$798,253 during the nine months ended September 30, 2021.

We expect our working capital requirements in the next year to be met primarily by the proceeds from theof issuance of notes payable duringdebt, equity and other securities to our existing creditors, shareholders, and other investors, as well as from cash flow from operations. We also expect that, as in the period.

The Company does not have sufficient capitalpast, significant amounts of our convertible debt with a major lender will be converted into equity. We expect to meet its current cash needs, which include the costs of compliance with the continuing reporting requirements of the Securities Exchange Act of 1934, as amended. The Company intends to seekneed additional capital and long term debt financing to attempt to overcome its working capital deficit. The Company will need between $50,000 and $100,000 annuallyfrom outside sources to maintain its reporting obligations. The Company may attempt to do more private placements of its stock in the future to raise capital, but therecover our anticipated operating expenses. There is no assurance that the Company canwill be able to raise sufficient additional capital or obtain sufficient financing to enable itcontinue in business or to obtain approvaleffectively execute its business plan.

COVID-19 Impact

The COVID-19 pandemic has had, and continues to have, a significant impact around the world, prompting governments and businesses to take unprecedented measures, such as restrictions on travel and business operations, temporary closures of its prototype frombusinesses, and quarantine and shelter-in-place orders. The COVID-19 pandemic has at times significantly curtailed global economic activity and caused significant volatility and disruption in global financial markets. The COVID-19 pandemic and the Federal Foodmeasures taken by many countries in response have affected and Drug Administrationcould in the future materially impact the Company’s business, results of operations and financial condition.

Certain of the Company’s outsourcing partners, component suppliers and logistical service providers have experienced disruptions during the COVID-19 pandemic, resulting in supply shortages. Similar disruptions could occur in the future.

Going Concern Qualification

Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to sustain monthly operations. In order to address itsrealize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the nine months ended September 30, 2022, we incurred a net loss of $2,607,703, had a working capital deficit the Company also intends to endeavor to (i) reduce operating costs, (ii) reduce general, administrativeof $7,268,825 and selling costs, (iii) increase saleshad an accumulated deficit of its existing products and services, and (iv) obtain the approval of the United States Food and Drug Administration to the Company’s proprietary medical imaging device so that the Company can commence marketing and selling it. There may not be sufficient funds available to the Company to enable it to remain in business and the Company’s needs for additional financing are likely to persist.

Going Concern Qualification

The Company has incurred significant losses from operations, and such losses are expected to continue. The Company’s auditors have included a “Going Concern Qualification” in their report for the years ended December 31, 2016, 2015, 2014, 2013 and 2012. In addition, the Company has limited working capital. The foregoing raises substantial doubt about the Company’s$19,433,867 at September 30, 2022. Our ability to continue as a going concern. Management’s plans include seeking additional capital and/concern is dependent upon our ability to generate profitable operations in the future and or debt financing.obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations as they come due. There is no guaranteeassurance that additional capital and/or debt financingthese events will be available when andsatisfactorily completed. As a result, there is doubt about our ability to the extent required, or that if available, it will be on terms acceptable to the Company. The financial statements do not include any adjustments that might resultcontinue as a going concern for one year from the outcomeissuance date of this uncertainty. The “Going Concern Qualification” might make it substantially more difficult to raise capital.these financial statements

Off-Balance Sheet Arrangements

None.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4. Controls and Procedures

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934 (the “Exchange Act”)adequate internal control over financial reporting as such term is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “SEC”), and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based closely on the definition of “disclosure controls and procedures”defined in Rule 15d-15(e)13a-15(f) under the Exchange Act. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how wellInternal control over financial reporting is a process designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

At the end of the period covered by this Quarterly Report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officerprincipal executive and Chief Financial Officer,financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.

28

As of September 30, 2022, our management assessed the effectiveness of our internal control over financial reporting using the design and operationcriteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Based on this assessment, our disclosure controls and procedures. Based upon the foregoing, our Chief Executive Officer and Chief Financial Officermanagement concluded that, as of September 30, 2017, the disclosure controls and procedures of2022, our Company were not effective to ensure that the information required to be disclosed in our Exchange Act reports was recorded, processed, summarized and reported on a timely basis.

Imaging3 is undertaking to improve its internal control over financial reporting and improve its disclosure controls and procedures. As of December 31, 2016 we had identified the following material weaknesses which still exist as of September 30, 2017 andwas effective based on those criteria.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting through the date of this report:

1. As of September 30, 2017, and as of the date of this report we did not maintain effective controls over the control environment. Specifically, the Board of Directors does not currently have any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-B. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.

2. As of September 30, 2017, and as of the date of this report, we did not maintain effective controls over financial statement disclosure. Specifically, controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements. Accordingly, management has determined that this control deficiency constitutes a material weakness.

3. As of September 30, 2017, and as of the date of this report, we did not maintain adequate segregation of duties. Accordingly, management has determined that this control deficiently constitutes a material weakness.

Changes in Internal Control Over Financial Reporting

There were no changes in internal controls over financial reporting that occurredor during the quarter ended September 30, 2017,2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

This report does not include an attestation report offrom our registered public accounting firm regarding internal control over financial reporting.

PART II. OTHER INFORMATION

Administrative Claim of Greenberg Glusker Fields Claman & Machtinger LLPItem 1. Legal Proceedings

On January 30, 2017 the Company entered into a new Agreement. Under the terms of the Agreement, the Company has agreed to pay Greenberg $1,117,574 plus any interest that has accrued at the rate of 6.0% per annum, as follows: (i) $100,000 on or before December 31, 2017; (ii) $150,000 on or before December 31, 2018 (iii) 4.0% of the first $2.5 million of gross proceeds of any private or public offering by the company (an “Offering”); (iv) 2.0% of the next $2.5 million of gross proceeds from such Offerings; (v) 4.0% of any gross proceeds thereafter from such Offerings; and (vi) the remaining balance on or before December 31, 2019.None.

In addition, Greenberg has the option to convert up to $150,000 of the balance into a warrant that would convert on terms that are equal to (or, in certain cases, better than) the terms offered in subsequent rounds of financing.

Bankruptcy Closure

On January 31, 2017, United States Bankruptcy Judge for the Central District of California, Neil Bason, granted the company’s unopposed motion for entry of final decree and also granted approval of the two stipulations regarding payment of court-approved fees. The Company noted that as a result, the Imaging3 Chapter 11 proceeding is now closed—the company is no longer subject to the jurisdiction of the Bankruptcy Court, and the case cannot be converted to a Chapter 7 proceeding.

To clarify, the Judge’s order in its final paragraph stated that “Notwithstanding the foregoing [order closing the bankruptcy case pursuant to 11United States Code Section 350(a)] the bankruptcy case may be reopened on motion as set forth in the Greenberg, Glusker Fee Agreement and/or the Mentor Group Fee Agreement and thus the court retains jurisdiction for those purposes and as otherwise provided by law or as contemplated by the prior orders and proceedings of this court”. Thusly, technically, the case could possibly be reopened by either of those aforementioned creditors.

Pending Litigation

On September 13, 2017 Alpha Capital Anstalt and Brio Capital Master Fund, LTD two minority members of a group of investors in the Company filed a lawsuit seeking damages and injunctive relief in the United States District Court for the Southern District of New York claiming that the Company breached certain Note and Warrant agreements among the parties to the action. The holders of the majority of the investment involved in the above lawsuit chose not to join in the lawsuit and have informed the Company that they believe the lawsuit to be baseless. The Company believes the lawsuit is without merit and is aggressively defending against it. The litigation is currently in its preliminary pleading stage and the Company is seeking to have the injunctive counts of the lawsuit dismissed for failure to state a cause of action.

Item 1A. Risk Factors

Not applicable because weSmaller reporting companies are a smaller reporting company.not required to provide the information required by this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales of equity securities during the period covered by this quarterly report.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

(a) Exhibits

EXHIBIT NO.DESCRIPTION
31.1Section 302 Certification of Chief Executive Officer
31.2Section 302 Certification of Chief Financial Officer
32.1Section 906 Certification
32.2Section 906 Certification
101.INSInline XBRL Instance Document
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

29

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IMAGING3, INC.
Dated: November 14, 2017By:/s/ Dane Medley
Dane Medley
Chief Executive Officer
and Chairman (Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

/s/ Dane MedleyBradley J. YouristDated: November 14, 201718, 2022
Dane Medley, Bradley J. Yourist
Chief Executive Officer
and Chairman (Principal Executive Officer)
/s/ Kenneth J. Biehl

Dated: November 18, 2022

/s/ Xavier AguileraKenneth J. BiehlDated: November 14, 2017

Xavier Aguilera, Chief Financial Officer
Secretary, and Executive Vice President
(Principal Financial/Accounting Officer)

30